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ABSTRACT 
Pluripotent Stem Cell Derived Retinal Pigmented Epithelium: 
Methods, Lines, and Behaviors 
 
by 
Roxanne Helene Croze 
 
 Ocular diseases affect millions world-wide and dramatically influence the quality 
of life. Although much is known about ocular biology and disease pathologies, effective 
treatments are still lacking. The eye is well suited for application of emerging cell-based 
therapies. This dissertation will explore the development of stem cell-based treatments 
for age-related macular degeneration (AMD), a prevalent ocular disease in the elderly. 
Retinal pigmented epithelium (RPE), a cell type implicated in AMD, has been derived 
from both human induced pluripotent stem cells (iPSC) and human embryonic stem 
cells (hESC). Rapidly advancing research has generated various methods of RPE 
differentiation and several transplantation strategies. The following chapters will 
provide an in-depth overview and characterization of hESC-RPE and iPSC-RPE across 
two methods of derivation. 
 Pluripotent stem cell derived RPE have unique cellular characteristics. This 
dissertation will also examine various RPE behaviors upon manipulation with a 
synthetic kinase inhibitor and describe the creation and production of exogenous 
reporters that can be used for real-time monitoring of cellular transplantations.  
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 Human embryonic stem cell derived retinal pigmented epithelium (hESC-RPE) is 
in clinical trials for the treatment of macular diseases. Currently, these cells take over 
three months to derive and subsequent months to mature and characterize. After only 
four to five passages the cells begin to undergo an epithelial-to-mesenchymal transition 
and are unsuitable for cellular therapies. We show in this dissertation that inhibition of 
Rho-associated coiled-coil kinase (ROCK) using specific inhibitor, Y-27632, can increase 
the lifespan and proliferation rate of hESC-RPE in culture. hESC-RPE maintain typical 
cuboidal morphology, gene expression, protein localization, factor secretion, and 
phagocytic abilities up to passage 13 following ROCK inhibition.  
 In addition, this dissertation will elucidate other effects of ROCK inhibition on 
hESC-RPE. ROCK inhibition is known to affect cytoskeletal rearrangements and we will 
show that ROCK inhibition can promote wound closure and attachment through 
increased cell cycle activation and cell spreading respectively. Elucidating these effects 
and beginning to understand the mechanisms of wound healing and attachment is 
critical when considering ROCK inhibition as a novel treatment for geographic atrophy, 
a late stage phenotype of AMD, and as a potential combinational therapy with cellular 
replacement to enhance engraftment. 
 In the final chapter, the creation of a molecular tool basket will be described. As 
hESC-RPE progress through the phases of clinical trials, it will be important to gain a 
better understanding of how the cells behave in vivo to address any potential caveats 
within the clinical trials. Fluorescent reporters that monitor transplanted cell migration, 
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function and mitotic stage have been created to examine, in real time, how the stem cell 
derived transplant is affected by the endogenous retinal milieu. 
 The findings within this dissertation have tremendous implications in 
understanding the variability between hESC-RPE and iPSC-RPE and the various 
methods of derivation as these cellular therapies move into the clinics. In addition, the 
benefits of ROCK inhibition on hESC-RPE and iPSC-RPE could lead to combinational 
therapies and help produce large intermediate cell banks if clinical trials prove efficient 
and a large scale cell production is required.  
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Chapter I 
 
Differentiation of Pluripotent Stem Cells into Retinal Pigmented Epithelium 
  2 
Introduction 
 Age-related macular degeneration (AMD) is a progressive disease leading to the 
loss of high-acuity vision. More than 200,000 people are diagnosed per year, making 
AMD the leading cause of blindness in the elderly in the developing world [1]. Around 
7.2 million people in the US alone suffer from this devastating disease with annual 
medical costs exceeding US$250B [2]. The disease primarily affects a small region in the 
back of the eye responsible for central vision called the macula. Loss or dysfunction of 
macular RPE, which provides crucial supportive functions for the photoreceptors, is 
thought to play a crucial role in disease progression.  There are two general forms of the 
disease, wet (exudative) AMD and dry (non-exudative) AMD, with over 90% of patients 
suffering from the more slowly progressing dry form [3, 4]. Wet AMD is characterized 
by a quick progression of choroidal neovascularization (CNV), leading to rapid 
degradation of RPE and photoreceptors and impaired vision. However, this form of the 
disease is successfully treated in most patients using inhibitors of the vascular 
endothelial growth factor (VEGF), such as ranibizumab, bevacizumab, and aflibercept 
[1, 5-7]. The advanced form of AMD not involving CNV growth, termed geographic 
atrophy, results in extensive RPE and photoreceptor death, which causes substantial 
vision loss as the fovea becomes threatened or involved directly [8, 9]. This extensive 
loss of vision impairs daily activities including reading, driving, face recognition, and 
mobility.  Currently, there are no reliable, effective treatments for dry AMD [10, 11]. 
Although some experimental autologous transplants and retinal translocation surgeries 
have been performed, they are fraught with obstacles and complications that have yet 
to be overcome [12]. 
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 AMD is a multifactorial disease with numerous genetic and environmental risk 
factors [13, 14].  Polymorphisms within multiple complement system genes, including 
alternate complement factors H, B, and I, in addition to components 2 and 3, lead to 
substantial genetic predisposition to AMD [15-21]. These findings suggest a chronic 
inflammatory state in the disease and potentially a progressive immune attack on RPE. 
Mutations in non-inflammatory related genes, Apolipoprotein E (APOE) [22], hepatic 
triglyceride lipase (HL) [23], cholesteryl ester transfer protein (CETP) [23], vascular 
endothelial growth factor (VEGF) [24], and regions surrounding the tissue inhibitor 
metalloproteinase 3 (TIMP3) [23], also correlate with AMD onset. Genes associated with 
AMD also include Age-related Maculopathy Susceptibility 2 (ARMS2) [21] and HTR1A 
serine peptidase 1 (HTRA1) [25], although little is known about their mechanisms of 
action. A mutation in the ATP-binding cassette transporter gene sub-family A (ABCA4) 
leads to Stargardt disease, causing early onset macular degeneration, often rendering 
patients blind before the age of 20 [26]. ABCA4 mutations may also be associated with 
some cases of AMD [27]. Environmental factors that influence AMD development and 
progression include, age, smoking, non-African decent, poor eating habits, and low 
physical activity [14]. The precise mechanism of AMD causation is still not completely 
understood. 
 The presence of drusen deposits is the hallmark pathology of both forms of AMD. 
Drusen are composed of lipids, carbohydrates, proteins, and cellular components, 
including secreted inflammatory proteins [28, 29]. These deposits build up in between 
the basal laminar side of the RPE and the surface of the Bruch’s membrane, a 
multilaminar extracellular matrix barrier separating the RPE and choroid. The 
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monolayer of RPE is disrupted by drusen and may play a role in RPE dysfunction. 
However, the direct effect of drusen on RPE and in AMD is still unclear [28]. Drusen 
biogenesis might cause RPE dysfunction, or RPE damage could lead to defective 
degradation of cellular components and consequent formation of deposits [30]. 
Regardless, drusen are present in AMD where RPE undergo apoptosis, contributing to 
photoreceptor death [31, 32]. 
 RPE are critical to photoreceptor viability [33, 34]. The RPE create the blood-
retina barrier and have multiple roles in maintaining photoreceptor health and visual 
function. RPE phagocytose rod outer segments, absorb of stray light, secrete trophic 
factors, and assist in visual cycle retinol conversion and nutrient diffusion from the 
choroid. Therefore, dysfunctional RPE leads to the subsequent damage and death of 
photoreceptors. Photoreceptor loss within the macula causes central vision impairment 
with disease progression expanding the extent of vision loss. 
 Retinitis pigmentosa (RP), Leber congenital amaurosis (LCA) and Best disease 
are also associated with RPE dysfunction and might benefit from novel cell replacement 
therapies. Current treatments, in various stages of development, involve gene therapy 
using associated adenoviral injections [35, 36]. Promising research using merTK gene 
therapy in mouse models of retinal dysfunction could lead to a novel RP treatment; 
merTK is a receptor located on the apical side of RPE, critical in phagocytosis of 
photoreceptor outer segments. RPE65 gene therapy is currently in clinical trials for LCA 
treatment. RPE65 is an RPE specific enzyme involved in the retinoid visual cycle, 
necessary for continual photoreceptor function [36]. To gain a better mechanistic 
understanding of these diseases, iPSC lines are being generated from patients. The 
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Gamm group has created several iPSC-RPE lines from Best disease patients to elucidate 
the normal and aberrant function and localization of Bestrophin, the protein genetically 
altered in this disease [37].  
The Case for Cellular Therapies 
 Current available treatment options for dry AMD are limited. Vitamin and 
mineral therapy can reduce the incidence of CNV but does not seem to affect the 
development of GA [38]. Although cell based therapies have challenges including, 
cellular production and characterization, immune rejection, inflammatory response, 
tumor formation, and integration and survival of the transplant, the eye has many 
advantages that make this approach feasible. The macula averages 6mm in diameter, 
requiring approximately 120,000 RPE cells for complete coverage. The sub-retinal 
space is immune-privileged, lacking significant immune cell infiltration. Lastly, the eye 
is accessible, and refined surgical techniques and tools are available for efficient 
subretinal transplantation. In addition, good end point parameters of transplant success 
can be measured. Visual acuity can be determined using simple tests (EDTRS Eye 
Charts) as well as more complex microperimetry. Advanced imaging techniques, such 
as optical coherence tomography (OCT) and fundus autofluorescence (FAF) can be done 
to assess transplant placement, RPE integrity, photoreceptor integrity, RPE-
photoreceptor integration, choroidal thickness, and complications such as retinal 
edema and CNV. Progress in imaging is continuing at a rapid pace, with the 
development of novel, non-invasive adaptive optic methods that can resolve single RPE 
and photoreceptor cells [39].  
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 Proof of concept for RPE transplantation comes from studies in rodents and 
humans that began 20 years ago. Extensive research has been carried out using a 
variety of cell types, transplantation methods and tools, and retinal dysfunction models 
[12]. In rodents, while there is no ideal model for AMD, the Royal College of Surgeons 
(RCS) rat is used as a model of RPE dysfunction. It is important to note that rats do not 
have a macula (including a cone-rich fovea), and the RCS rat model does not 
recapitulate some critical aspects of human AMD (e.g., abnormalities in Bruch’s 
membrane structure and composition). RCS rats harbor mutations in the merTK gene, 
which encodes a cell surface receptor required for the critical RPE process of 
photoreceptor outer segment phagocytosis. Without proper phagocytosis, RPE fail to 
maintain photoreceptor viability, causing substantial vision loss 3 months after birth. A 
number of cell types will rescue vision in this model. Suspensions of transformed and 
spontaneously derived RPE cells, h1RPE7 and ARPE19, injected into the subretinal 
space show improved visual performance and histology compared to sham-treated RCS 
rats [40-43]. Isolated fetal human neural cortical precursor (hNPCs) cells also rescue 
visual function after injection. These precursors migrate to the retina and form a 
multilayer on Bruch’s membrane, increasing retinal sensitivity and function [44]. 
Although fibroblasts will not effectively rescue vision in the RCS rat some salutary 
effects are observed in animals undergoing subretinal injection without cell delivery 
[45]. In addition, the photoreceptor rescue effect often extends hundreds of microns 
beyond the border of the transplanted cells [43]. Therefore, it seems likely that 
secretion of trophic factors and activation of endogenous macrophages that clean up 
the debris zone contribute to the rescue and preservation of photoreceptors.   
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 To date, human RPE transplantation has utilized three types of RPE: autologous, 
allogenic, and stem cell-derived. Autologous RPE transplantation involves excision of a 
patch of healthy RPE plus choroid from the ocular periphery and placement under the 
macula. Macular translocation, another form of autologous surgery, originally used to 
treat exudative AMD patients, involves retinal detachment and rotation, locating 
healthy RPE and Bruch’s membrane under the macula. However, when macular 
translocation is done to treat GA, GA develops rather rapidly under the new location of 
the fovea for unknown reasons [46]. Fetal and cadaver RPE have been injected in 
suspension, small sheets, or gelatin matrices into patients with varying ocular diseases 
to improve visual performance [12]. There is a suggestion that better results have been 
obtained with patches or sheets, rather than suspensions of cells [47, 48]. The results of 
RPE transplantation studies in AMD patients have been variable, however, and time will 
tell which method proves to be superior [49]. The relatively few documented cases of 
visual improvement following RPE transplantation demonstrate the cellular therapy is 
feasible and may be a useful approach for treating selected AMD patients. 
 A number of important issues must be addressed for cell-based AMD therapy to 
be optimized, e.g., long-term cell survival (independent of immune rejection), 
identification of the stage(s) of the disease most appropriate for surgical intervention, 
and development of a safe, simple surgical technique. A critically important issue also 
involves identification of sources of cells for transplantation. Apart from ethical 
concerns, fetal RPE are not available in abundance and cannot be propagated 
indefinitely (abnormal morphology is evident by the fifth passage in most cases), which 
limits their commercial utility. The ideal cell source for therapies would have infinite 
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expansion properties, reproducible and well-defined differentiation capabilities, and 
stable cryopreservation and shipment abilities. Human pluripotent stem cells meet the 
starting cell material criteria for the large source of RPE needed for ocular disease cell 
therapy. 
 In this chapter, we will discuss the methods of RPE derivation from pluripotent 
stem cells and the various transplantation methods undergoing development as cell 
therapies move forward into the clinics. While many excellent reviews have been 
written on this topic [47, 50-52], the field is developing fast enough to warrant a new 
discussion.  
Derivation of RPE from Pluripotent Stem Cells 
 There are two main types of human pluripotent stem cells: human embryonic 
stem cells (hESCs) and induced pluripotent stem cells (iPSCs). hESCs are harvested 
from the inner cell mass of a 3-5 day old fertilized embryo. hESCs can be cultured 
indefinitely with maintained stem cell characteristics and the potential to differentiate 
into all three germ layers [53]. The first five hESC lines generated in 1998 by Prof. Jamie 
Thomson’s laboratory at the University of Wisconsin are still in use today. Theoretically 
these lines could be used to supply enough cells for research and treatment of all 
patients of any disease for which cellular therapies are developed, including AMD. iPSCs 
are derived from differentiated somatic cells that have been reprogrammed to revert 
back to a pluripotent state. This reprogramming was first accomplished using 
integrative viral vectors encoding specific embryonic transcription factors associated 
with pluripotency. The stem cell colonies that formed, like hESCs, could divide infinitely 
and differentiate into any cell type in the body [54, 55]. The potential advantage of 
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iPSCs over hESCs is that patient-specific cells could be generated that might avoid 
immune rejection after autologous transplantation. While initial reports suggested that 
autologous undifferentiated iPSCs might still be rejected [56], more recent studies have 
shown that differentiated cells are immune compatible [57, 58]. Improved methods for 
generation of iPSCs that lack integrating vectors have been discovered that utilize 
excisable transgenic systems, micro RNAs, modified mRNAs, and small molecules[59-
63]. Thus, both iPSCs and hESCs are promising sources for future cellular therapies.  
 Numerous cell types have been derived from both hESCs and iPSCs including 
RPE. RPE differentiation from hESCs was first described in 2004 by Klimanskaya et al., 
and since then multiple groups have optimized the protocol for producing a pure 
population of hESC- and iPSC-derived RPE (hESC-RPE) (iPSC-RPE) [40, 47, 50, 64-74]. 
In culture, stem cells and RPE need to be grown on a substrate to support their 
attachment and growth. hESCs and iPSCs originally were grown on inactivated mouse 
or human embryonic fibroblasts; however, Matrigel, a composite of extracellular matrix 
proteins from a mouse sarcoma, and mouse PA6 stromal cells have also been used [53-
55, 64, 75]. Endogenous RPE normally reside on an extracellular matrix layer called 
Bruch’s membrane. In culture, a similar substrate is needed to facilitate RPE 
attachment, differentiation, and survival. Several substrates have been used: human 
Bruch’s membrane explants, gelatin, laminin, vitronectin, bovine corneal endothelial 
cell extracellular matrix, and Matrigel. Comparisons show that Matrigel, laminin, 
vitronectin, and bovine corneal endothelial cell extracellular matrix lead to the purest 
RPE phenotype [76-78]. Ideally a xenofree (non-animal containing) protocol would be 
used throughout the entire differentiation process. 
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The Continuous Adherent Culture Method 
 Derivation of RPE from either pluripotent starting source can be achieved in a 
continuous adherent culture. Stem cells are allowed to overgrow on a feeder cell layer 
of mitotically inactivated mouse embryonic fibroblasts (MEF) or Matrigel. Stem cell 
colonies become confluent and multilayered. They lose their tight borders and begin to 
differentiate. At this time, the media is changed from a stem cell supporting media, to a 
differentiating media without basic fibroblast growth factor (bFGF) to further promote 
differentiation. Cultures maintained in this bFGF-free media will begin to show small 
spots of pigmentation after 1-8 weeks. These spots are differentiating RPE. Overtime, 
the pigmented spots multiply and expand within the culture. Although there are other 
differentiated cell types in the cultures, the spontaneously derived RPE are easy to 
distinguish because of their pigment granules, a major advantage in hESC/iPSC-RPE 
differentiation. When the pigmented RPE spots become frequent and large, they can be 
mechanically dissected and passaged [40, 65-67, 73, 79, 80]. The excised cells are 
grown to a monolayer and exhibit the RPE-distinctive cobblestone morphology and 
pigmentation patterns (Figure 1). The downside of this RPE enrichment method is that 
the manual isolation technique is difficult to fit within the Good Manufacturing Practice 
(GMP) production guidelines. This limitation could prevent advancing hESC/iPSC-RPE 
cellular therapies into human clinical trials. Therefore, enzymatic techniques are under 
investigation to separate RPE from other differentiated cell types [80]. 
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Figure 1. Depiction of spontaneous retinal pigmented epithelium (RPE) differentiation 
from human embryonic stem cells (hESCs) using a continuous adherent culture method. 
(A) From left to right, overgrown hESCs through the spontaneous differentiation 
process. Pigmented colonies are manually excised after 100 days in culture and re-
plated to yield a mostly homologous population of RPE cells. (B) Enriched RPE exhibit 
typical cobblestone cuboidal morphology and pigmentation. Scale bar (A) 10mm. Scale 
bar (B) 100µm. 
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 After the pigmented RPE are enriched and plated, quality control must be 
performed to ensure these derived cells express similar gene expression patterns and 
function as endogenous RPE. Assays to establish RPE identity and potency must be 
created. Quantitative real-time PCR (QRT-PCR) can be done to compare transcript 
levels of hESC and iPSC-RPE to human RPE. A number of RPE genes (e.g., RPE specific 
transcription factors, microphthalmia-associated transcription factor (MITF) and 
orthodenticle 2 isoform b homeobox protein (OTX2); visual cycle proteins, cellular 
retinaldehyde-binding protein (CRALBP) and retinal pigmented epithelium protein 
65kDa (RPE65); secreted factors, pigment epithelium-derived factor (PEDF); tight 
junction marker, zona occludens 1 (ZO-1); and phagocytosis component, mer tyrosine 
kinase (MERTK)) are analyzed by QRT-PCR to ensure mRNA levels coincide with human 
fetal RPE (fRPE) [40, 65-67, 73, 79]. Current data suggest some differences between 
fRPE, the benchmark comparison. Overall, bioinformatics analyses show that hESC-RPE 
are very similar to fRPE but may correspond to a less mature RPE state [73]. RPE65, a 
mature RPE marker, appears to increase with culture of hESC-RPE, and could also be 
used as a biomarker to determine RPE identity. It is interesting to note that fRPE share 
a much more similar gene profile with hESC-RPE than iPSC-RPE [73]. In addition, hESC-
RPE and fRPE show equivalent low levels of genes associated with aging, energy 
metabolism, and the complement system, all factors associated with AMD 
pathophysiology [73] (Hikita et al. unpublished). 
 Stem cell-derived RPE must also be tested to ensure these cells carry out critical 
physiological processes. As described previously, RPE are responsible for 
phagocytosing photoreceptor outer segments to maintain photoreceptor homeostasis. 
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Phagocytosis can be tested using an assay in which fluorescently labeled outer 
segments are incubated with cultured RPE, and the amount of internalized segments is 
quantified. hESC-RPE and several iPSC-RPE lines have phagocytic abilities comparable 
to fRPE [66, 67, 73, 76, 79]. Several studies have implanted both types of stem cell-
derived RPE into rodent models of retinal dysfunction and shown improved visual 
performance [40, 65, 68, 81]. In addition, subretinally injected iPSC-RPE enhanced 
visual acuity in a model of RP with no tumor formation [82]. Currently, all clinical trials 
involving hESC-RPE require immunosuppression, which could potentially be avoided if 
a well-defined, rapidly developed iPSC-RPE line could be generated. One example of 
such an approach, uses only Oct4 to reprogram into iPSCs in combination with small 
molecules [83]. These lines have been derived into RPE and hold great potential for 
clinical application of autologous RPE grafts. 
The Embryoid Body Approach 
 hESCs and iPSCs can also be differentiated into RPE using a second strategy 
called the embryoid body approach. Although this method may not be as efficient as the 
continuous adherent approach, it still yields viable RPE and is a spontaneous 
differentiation protocol [65]. To apply this method, stem cells are grown on feeder cells 
or substrate until 50-75% confluent. Colonies are dissociated using an enzyme, such as 
collagenase, and sectioned into pieces. The pieces are plated in a serum- and bFGF-free 
differentiation media on plates coated with a neutrally charged hydrophilic hydrogel to 
diminish attachment. The cells will form spherical aggregates called embryoid bodies 
(EBs). These bodies can differentiate into all three germ layers and show pigmentation. 
Twenty days following EB formation, the aggregates are passed onto a coated plate, 
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allowing for cell attachment. Within 24 hours cells will attach and begin to spread. Over 
time, distinct RPE sheets will form. These RPE colonies can be excised manually and 
passaged onto another coated dish, creating a mostly homogenous RPE cell population 
[68, 69, 72, 79, 84]. Gene expression profiles of resultant hESC -RPE cells show patterns 
similar to fRPE, with robust expression of RPE specific genes: MITF, OTX2, CRALBP, 
RPE65, PEDF, ZO-1, MERTK [68, 69, 72, 74, 84]. In addition, these cells can phagocytose 
outer segments and rescue visual performance in rodent models of retinal dysfunction 
[68, 72, 79, 84]. This desired phenotype can also be achieved deriving RPE from iPSCs 
[69, 71, 85-87].  
Directed Differentiation 
 Spontaneous differentiation of RPE is time consuming and efficiency varies 
between cell lines. Therefore, a number of groups have focused on improved protocols 
to speed up this process. The strategy is to mimic normal human RPE development by 
adding small molecules to initiate signaling cascades at the correct time to promote 
retinal cell fate in vitro [69-71, 84]. These efforts have not only focused on hESC and 
iPSC differentiation into RPE, but also on a range of retinal cell types [88]. RPE are 
ectoderm and originate from the anterior neural plate neuroepithelium during optic 
cup development. A range of signaling cascades including the transforming growth 
factor-beta (TGFβ) superfamily, Wingless-related integration site (Wnt), and fibroblast 
growth factor (FGF) pathways are involved in RPE specification [33, 89]. Stem cells 
must first be directed towards a retinal progenitor fate before terminal RPE 
differentiation. Several groups have directed differentiation by using Wnt and NODAL 
inhibitors, Dkk-1 and Lefty-A, to induce a neural fate [70, 71, 74, 84]. Further neural and 
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retinal induction has been obtained utilizing supplements, N2 or B27 and heparin. 
Following differentiation into retinal progenitors, RPE can be specified by epithelial 
driving factors. Activin A, BMP4, Wnt3A and an FGF inhibitor (SU5402) stimulate RPE 
derivation from neural retinal progenitors [69]. A class B vitamin, nicotinamide, also 
promotes RPE differentiation, and this effect is enhanced when added in combination 
with Activin A [72]. Appropriate timing and duration of each molecule is critical to yield 
pigmented, functional RPE. In 2012, Zahabi et al. reduced the time from beginning 
human iPSC differentiation to enrichment to 40 days using basic FGF (bFGF), TGFβ 
receptor inhibitor (SB431542), noggin, retinoic acid (RA), and sonic hedgehog (shh) 
throughout their protocol [90]. A new method of deriving RPE from pluripotent stem 
cells was published by the Tanaka group in January, 2013. They described the 
formation of epithelial cysts, mimicking neural tube morphology, arising 5 days after 
pluripotent cells are embedded in Matrigel. The cysts are extracted, re-plated onto 
Matrigel-coated wells using an RPE supporting media with supplemental factors, and 
develop into RPE within 30 days. These RPE become pigmented, express RPE65 and 
BEST1, show appropriate transepithelial resistance levels, and phagocytose rod outer 
segments. In addition, following transplantation into the RCS rat, they increase the 
thickness of the outer nuclear layer within the retina [91]. Recently an improved 
protocol of directed differentiation from hESCs to RPE has been achieved, producing 
enrichable RPE sheets within only 14 days [75]. This protocol has been refined further 
through the use of CHIR99021, leading to a further increase in RPE derivation efficiency 
[92] (See Figure 2 for a comparison of all differentiation methods.) 
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Figure 2. Time course comparison of the continuous adherent culture and embryoid 
body culture methods of spontaneous derivation of RPE from pluripotent stem cells. 
Colored lines indicate time to enrichment for other RPE differentiation methods. 
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Other sources of RPE 
 While pluripotent stem cells are the best source of RPE, other stem cell types are 
under investigation. Both rat neural stem cells, harvested from the cerebral cortex, and 
mesenchymal stromal cells (MSC), isolated from human lipo-aspirate, were reported to 
yield cells with some RPE characteristics using the same differentiation strategy [93, 
94]. Co-cultures with rat RPE, or conditioned media from human RPE, in combination 
with vaso-intestinal peptide (VIP) produced cells with some morphological features of 
RPE [93, 94]. The MSC-derived RPE were further characterized and showed some 
induction of BEST1 and RPE65, mature human RPE markers [94]. However, the levels 
of expression were not compared to fRPE, so it is difficult to be sure how RPE-like these 
cells are. Another group used bone marrow-derived mesenchymal stem cells cultured 
with human RPE-conditioned media and photoreceptor outer segments to generate 
RPE that express RPE65 and phagocytose porcine rod outer segments [95]. Another 
potential alternate source of RPE is retinal stem cells (RSCs) from the ciliary margin. 
Coles et al. reported that there are 10,000 multipotent RSCs in each eye that can yield 
all retinal cell types, including RPE [96]. After transplantation of RSCs into mice, the 
cells survived, integrated, and differentiated into the retina. However, a subsequent 
study questioned whether these were actually RSCs [97]. It is unclear if these cells can 
be expanded into a pure RPE population, and more characterization is needed. During 
development, RPE are plastic cells, and some groups have harnessed this potential in 
mature RPE, claiming RPE can dedifferentiate into a multipotent stem cell which can 
then take on other cell phenotypes [98]. 
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 A direct conversion of human fibroblasts to RPE-like cells has also been achieved 
through over expression of key RPE transcription factors and additional supplements. 
This protocol yields cells expressing some mature RPE markers within 35 days. The 
function of these RPE-like cells, however, has not yet been reported [99].   
iPSC or hESC-derived RPE? 
 An unanswered question remains: which starting source, hESCs or iPSCs is 
better for clinical use? A potential drawback to the iPSCs having the same genetic 
makeup and immunocompatibility as the patient is that they carry the same inherited 
defects predisposing to the disease. Another caveat is that these cells show increased 
mutations, copy number variations, and abnormal methylation patterns when 
compared to hESCs, which could hinder their therapeutic value [86, 100-104]. hESC-
RPE are a younger cell type and are not manipulated by viruses or small molecules. 
Although, allogeneic hESC-RPE can be free of disease-associated mutations, they might 
be rejected by the immune system. The subretinal space is an immune privileged sight, 
but this privilege is relative and not absolute. Moreover, patients may have a 
compromised blood-brain barrier, which could allow a larger than normal immune 
response within the eye. A benefit of hESC-RPE is they can be ready for transplantation 
immediately following diagnosis in appropriately selected patients. Currently, patient-
specific iPSC-RPE would be extremely time consuming to produce and characterize 
before transplantation. In patients with rapidly progressing disease, this delay in 
treatment might result in significant loss of vision. Finally, generation of autologous 
cells would be costly and require a nine month tumorigenicity study under current FDA 
policies. However banks of HLA-matched iPSCs might overcome this problem. 
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  iPSC-RPE also show memory of their previous terminal fate and show 
differences in gene profiles from fRPE [105]. These differences, however, vary from cell 
line to cell line, and with new non-integrative systems, iPSC-RPE appear to be more 
similar to fRPE [55, 73, 83]. There is great variability between cell lines for both hESC- 
and iPSC-derived RPE, which has yet to fully be explained and could lead to clinical 
complications for either source [69, 85, 106, 107]. More hESC-RPE and iPSC-RPE 
research is needed to elucidate the optimal starting cell material. Therapies moving 
forward with either cell line must take precautions to ensure reliable and fully 
characterized cells are manufactured for transplantation. 
Transplantation Strategies 
 In addition to the debate over whether to use hESCs or iPSCs to derive RPE for 
transplantation, there is also a question about how to deliver the cells. Grafted cells 
must integrate and function properly with the existing retina to prevent further 
photoreceptor damage and decrease progression of disease. Two main techniques are 
being studied currently. The first technique administers a bolus injection of dissociated 
RPE into the subretinal space. Both hESC-RPE and iPSC-RPE have been delivered with 
this approach, and both showed photoreceptor rescue and preserved vision in rodent 
models of retinal dysfunction [40, 65, 72, 81]. An important study in 2009 showed some 
transplanted cells, in two distinct rat models of ocular disease, survived the duration of 
the 220 day experiment with no teratoma formation [68]. This study is crucial in proof 
of principle that cells implanted into the eye can possess the longevity needed to slow 
disease progression without tumor formation [68]. However, efficiency of cell survival 
and integration are still in question. Some reports have concluded that the majority of 
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injected cells form aggregates in the subretinal space, do not integrate into the RPE 
monolayer, and are unaccounted for after a period of time. Importantly, only a subset of 
injected dissociated cells possesses the ability to phagocytose rod outer segments [81]. 
These results are not surprising. It is known that epithelial cells, like RPE, need to 
maintain contact with a basement membrane to function properly and remain viable 
[12]. Cells in suspension undergo ‘anoikis,’ a term coined by Ruoslahti to describe cells 
that undergo apoptosis after being displaced from their anchor of extracellular matrix 
proteins [108]. Bruch’s membrane has specific extracellular matrix proteins that are 
required for RPE adhesion, survival and function [34]. It is also crucial that RPE cells 
form tight junctions to fulfill their necessary barrier functions.  
 The above considerations suggest a second strategy for RPE transplantation: 
grow RPE on a scaffold substrate that mimics the support of the Bruch’s membrane and 
allows the RPE to be transplanted as a fully differentiated, polarized monolayer. The 
idea behind the scaffold technique is that RPE cells will survive longer and remain 
located over the diseased retinal area, leading to greater functionality and improved 
visual performance. In addition, RPE grown on substrates can polarize and be 
implanted in the correct orientation with their apical microvilli facing the 
photoreceptor outer segments [109]. In AMD, Bruch’s membrane deteriorates along 
with the RPE, therefore transplanting healthy RPE on a biomimetic scaffold could 
improve the functionality and long-term survival of the RPE transplant [110].  
 A variety of scaffolds have been investigated. Natural biomaterial scaffolds 
include: human amniotic membranes (hAM) [111-115], human lens capsule [116, 117], 
and explants of Bruch’s membrane [118, 119]. Using these unaltered natural tissue 
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supports could lead to issues with disease transmission from host and would be 
difficult to conform to FDA guidelines for transplantation production [120]. Natural 
polymers could be more advantageous and are currently being purified and used to 
grow hESC-RPE and iPSC-RPE. Extracellular matrix (ECM) proteins secreted from RPE 
[121] and corneal endothelial cells [121, 122], isolated gelatins and collagens [118, 121, 
123-126], alginates [109], hyaluronic acid [109], fibrinogens [127], vitronectin [118, 
119], laminins [118, 119, 122], and fibronectins [119, 122] all can support RPE growth. 
In addition to human purified proteins, a combination of ECM proteins derived from the 
mouse Englebreth-Holm-Swarm tumor called Matrigel is also efficient for culturing RPE 
[125]. The caveats to using ECM proteins are the lot-to-lot variation in composition and 
the difficulties to regulate production using GMP due to the animal source of the 
substrate. 
 Search for a synthetic polymer to support RPE growth and maturation has 
yielded several promising candidates. These compounds can be manufactured with 
knowledge of specific composition, are tailored to optimize RPE growth, and can be 
mass produced. In addition, adhesive peptides and growth factors can be embedded 
within the polymers to promote attachment and survival. Materials are non-
immunogenic and can be biodegradable or biostable supports. Parylene, poly (lactic-co-
glycolic acid) (PGLA), poly (L-lactic acid) (PLLA), polycaprolactone (PCL), poly (glycerol 
sebacate) (PGS), and polyhydroxyalkanoates (PHAs) are among those that have been 
investigated [109]. The polymers that successfully allowed culturing of RPE include: 
PLGA [128-132], PLLA [128, 132, 133], a polyethylene glycol (PEG)-PLLA [130], 
polydimenthylsiloxane (PDMS) [134], poly (hydroxybutyrate-cohydroxyvalerate) (PHB-
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co-PHV) [135], polyether urethanes [136, 137], and parylene [138]. Parylene is already 
approved for use in the eye, and it can be micromachined to include ultrathin areas that 
mimic the permeability of Bruch’s membrane. Hydrogels composed of methacrylate and 
(meth) acrylamide also promote RPE growth [115]. Current research is making 
progress toward completely xeno-free derivation of RPE from hESC and iPSC, and 
discovering the optimal synthetic scaffold would allow the entire process from 
differentiation to transplantation to be xeno-free. This approach provides benefits 
when creating GMP protocols and potentially eliminates complications from using 
animal products within the transplant [85, 139]. 
Clinical Trial Progression 
 Many groups are well on their way to bringing pluripotent stem cell-derived RPE 
cells to the clinic for treating ocular diseases like AMD. The first clinical trial was 
granted approval after long-term safety experiments and proof of concept were 
documented in rodents. Clinical trials began with two patients, one with Stargardt 
macular dystrophy and one with AMD. A bolus injection of dissociated hESC-RPE cells 
was administered into one eye of human patients. A preliminary report was published 
four months post transplantation [140]. Improved visual performance in the Stargardt 
disease patient was documented in the surgical eye only, but there is some controversy 
regarding this result [141]. The AMD patient showed improvement in the uninjected 
eye as well as in the injected eye, even though the immunosuppressive regimen was not 
followed. Perhaps the most important result from this preliminary study is that patients 
presented no loss of vision or formation of ocular tumors. The next round of patients 
enrolled in the study will receive a greater number of hESC-RPE cells with the intent of 
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increasing integration and efficiency [140]. Trials for wet and dry AMD using 
monolayers of hESC-RPE on scaffolds are soon to begin in London and California, and a 
trial using autologous iPSC-RPE has been approved in Japan. Other trials for AMD using 
non-RPE cells (neural stem cells and cord blood) have also been initiated. Because the 
eye has many advantages for developing cellular therapies, a number of groups have 
seized upon the opportunity. It seems likely, based on proof of concept studies in both 
rodent and human, that these trials have tremendous potential for the treatment of 
AMD as well as other ocular diseases.  
 This chapter published as Croze et. al (2014) in Developmental Ophthalmology, 
has outlined the ocular diseases and cell type of interest in the Clegg lab and the work 
being performed throughout the research community to create effective novel 
therapeutics to treat those affected by vision loss. The second chapter will compare 
several iPSC-RPE lines and two different methods of RPE differentiation to show the 
variability and caution that must be taken when choosing iPSC-RPE lines to use in the 
clinic. The third chapter, published as Croze et. al 2014 in Stem Cells Translational 
Medicine, and fourth chapter will examine the effects of Rho-associated coiled-coil 
kinase (ROCK) inhibition on various behaviors of hESC-RPE and iPSC-RPE including: 
passage length, proliferation, EMT, wound healing and attachment. Lastly, Chapter 5 
will describe molecular tools that have been created in order to gain valuable insight 
into how RPE behave after transplantation in a rat model of retinal dysfunction, in real 
time. 
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Induced pluripotent stem cell-derived retinal pigmented epithelium: A comparative 
study between cell lines and differentiation methods 
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Introduction 
 Induced pluripotent stem cells (iPSCs) were first described in landmark papers 
by the Yamanka and Thomson laboratories in 2006 and 2007, respectively [1, 2].  They 
described the reversion of differentiated cells back into a stem cell like state through 
the forced expression of key pluripotent genes. IPSCs have the potential to differentiate 
into any cell type in body, allowing for patient-specific cells to be created for possible 
treatment options [1, 2]. IPSCs hold great potential for novel autologous cellular 
therapies, disease modeling and research without many of the ethical concerns of using 
human embryonic stem cells (hESCs) [3]. First reports of iPSC lines were created using 
integrating vectors; however this could cause unwanted residual effects post 
differentiation [4]. Therefore, researchers have discovered ways to use non-integrating 
episomal vectors to derive iPSCs. Using non-integrating iPSC lines is extremely 
attractive when progressing these novel therapies towards clinical trials [5]. 
 The first iPSC clinical trial is underway in Japan to treat wet age-related macular 
degeneration (AMD) after several groups showed an improvement in vision following 
cellular injection in rat models [6-8].  AMD affects 7.2 million people in the United 
States and is the leading cause of blindness in the elderly population [9, 10]. There are 
two forms of the disease, wet, or exudative, and dry, or atrophic, AMD. Wet AMD is 
characterized by neovascularization within the retina while dry AMD presents with 
drusen, which are lipid deposits of unknown origin [11].  Both forms result in 
disruption of the retinal pigmented epithelium (RPE), a monolayer of cells situated 
between the choroid and the neural retina. The RPE are responsible for maintaining the 
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health of the photoreceptors; therefore when the RPE become compromised, the 
photoreceptors begin to die resulting in a loss of vision [12].  
 As iPSC-RPE begin to be used in clinical trials it is imperative that a more 
complete understanding of these cells is achieved to understand the variability that is 
known to exist between lines [13]. In addition, there are currently several methods for 
deriving RPE from hESCs and iPSCs; however, there has not been in-depth analysis of 
derivation methods for different lines of iPSCs [14, 15].  This article will provide a 
comparative study of three iPSC-RPE lines and two differentiation protocols: the 
spontaneous continuously adherent culture (SCAC) differentiation method [8, 15-19] 
and the 14-day directed differentiation protocol [20, 21].  
 In addition to an in-depth comparison of lines and derivation methods, we also 
compare a variety of genetic markers and physiological functions indicative of 
differentiated RPE that may be used to represent the quality of the iPSC-RPE line to 
determine whether it is suitable for transplantation. Development of a release assay, a 
single test to determine quality of derived cells, will be important because many groups 
are planning to create human leukocyte antigen (HLA) matched super banks of iPSC. 
These banks will avoid the long derivation and testing time that it takes to create 
autologous patient specific cells [22]. It is thought that HLA matching will dampen any 
immune response following transplantation [23]. Determining a proper release assay 
will expedite the efficiency of creating quality transplant-ready HLA matched iPSC-RPE. 
Methods 
Cell Culture 
Human Pluripotent Stem Cell Culture 
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  Epstein-Barr vector (EBV)-derived iPSC lines DF4-3-7T and DF19-9-11T [24, 
25] were both kindly donated from the James Thomson and David Gamm groups 
(WiCell Research Institute, Madison, WI), and the MyCell iPSC line (no. 1013.201) was 
acquired from Cellular Dynamics International’s MyCell iPSC Cell Services (Madison, 
WI). The hESC lines used for comparison were obtained from J. Thomson (H9s) and the 
University of California, San Francisco (UCSF4s; NIH registry No. 0044). All iPSC and 
hESC lines were maintained on Matrigel (BD Biosciences, San Diego, CA) in mTeSR1 
media (Stem Cell Technologies, Vancouver, BC, Canada). Cells were kept at 37°C 5% CO2 
in normoxic conditions and media was changed every other day.  
Retinal Pigmented Epithelium: Spontaneous Continuously Adherent Culture (SCAC) 
Differentiation Method 
Pluripotent stem cell lines were overgrown for 8-14 days; after which mTeSR1 
medium was changed to XVIVO-10 medium without basic fibroblast growth factor 
(bFGF; Lonza, Walkersville, MD). XVIVO-10 medium was changed every other day for 
90 days; pigmentation appeared approximately 1 month after medium switch. 
Following 90 days in culture, non-pigmented cells were manually dissected away from 
RPE pigmented spots. Cells were washed with phosphate buffered saline (PBS, Life 
Technologies, Carlsbad, CA), leaving only the pigmented patches adhering to the plate. 
Remaining pigmented cells were enzymatically digested using TrypLE Express (Life 
Technologies) for 5 minutes at 5% CO2 37°C. Cells were collected, diluted in 1:10 
volumes of XVIVO-10 and triturated, then spun at 1000 rpm for 5 minutes. The 
resulting pellet was resuspended in XVIVO-10, strained through at 30µM sieve and 
seeded onto Matrigel-coated plates at 1.0x105cells/cm2 creating a homogenous 
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population of enriched RPE cells.  XVIVO-10 medium was changed every 2-3 days and 
cells were maintained at 5% CO2 37°C in normoxic conditions. After RPE matured in 
culture for 30 days, they were passaged using TrypLE Express and plated again at 
1.0x105cells/cm2 on a Matrigel-coated surface in XVIVO-10 medium as described above. 
Cells were passaged using this method until passage 2 when they were cryopreserved, 
generating intermediate cell banks (ICBs).  
Retinal Pigmented Epithelium: 14-day Directed Differentiation Protocol 
Pluripotent stem cells were directed to differentiate to RPE in 14 days as 
previously described [20, 21]. Briefly, iPSC and hESC were passaged with EDTA (Life 
Technologies) using the methods described by Beers et al. [26] and seeded onto 
Matrigel-coated 12-well plates in DMEM/F12 medium containing 1 X N2, 1 X B27, and 1 
X NEAA (basal medium) (Life Technologies). From days 0-2 of differentiation, basal 
medium contained 10mM nicotinamide (NIC; Sigma-Aldrich, St. Louis, MO), 50ng/mL 
noggin, 10ng/mL Dkk1, and 10ng/mL IGF1 (R&D Systems Inc., Minneapolis, MN). From 
days 2-4, basal medium contained 10mM nicotinamide, 10ng/mL noggin, 10ng/mL 
Dkk1, 10ng/mL IGF1, and 5ng/mL bFGF. From days 4-6, 10ng/mL Dkk1, 10ng/mL 
IGF1, and 100ng/mL Activin A (Peprotech, Rocky Hill, NJ) was added to basal medium. 
From days 6-8, basal medium contained 100ng/mL Activin A and 10µM SU5402 (Santa 
Cruz Biotechnology Inc., Dallas, TX). From days 8-14, basal medium contained 
100ng/mL Activin A, 10µM SU5402, and 3 µM CHIR99021 (Stemgent, Cambridge, MA). 
On day 14, cells lacking RPE morphology were manually scraped away using a pipette 
tip, leaving only RPE-like cells in the culture dish. The RPE left behind were 
enzymatically digested using TrypLE Express for 5min at 5% CO2 37°C. Cells were 
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collected, strained, and seeded onto Matrigel-coated plates in XVIVO-10 medium at 
1.0x105cells/cm2 using the methods described above for the SCAC method. XVIVO-10 
medium was changed every 2-3 days and cells were maintained at 5% CO2 37°C in 
normoxic conditions. 14-day-derived RPE cells were expanded by passaging every 30 
days (as described above) and cryopreserved at passage 2 to generate ICBs.  
Creation of Intermediate Cell Banks (ICBs) 
 Cells were frozen down prior to reaching confluence, 2-4 days following plating, 
at passage 2.  Cells were lifted using TrypLE Express for 5 minutes at 5% CO2 37°C, 
gently scraped, triturated and diluted in 1:10 volumes of XVIVO-10. Cells were spun 
down at 1000 rpm for 5 minutes and then resuspended in CryoStor CS10 freezing 
medium (Stem Cell Technologies), at 3-6x106cells/ml. One ml aliquots were stored in 
cryovials and put into a slow rate freezing device and stored in the -80°C freezer for 24 
hours, following which cells were moved to liquid nitrogen for long term storage. ICBs 
were created of each viable iPSC-RPE line (reference Supp. Table 1 for non-viable iPSC-
RPE). HESC-RPE used for comparison were passaged and handled using the same 
methods as the iPSC-RPE. All cells used in analysis were thawed cells from ICBs, plated 
at passage 3 and seeded at 1.5x106cells/cm2. ICBs were created using at least 3 separate 
enrichments and expansions for each iPSC-RPE line. For all experiments and figures, 
three separate enrichments were performed and tested, n=3. 
Real Time Quantitative Polymerase Chain Reaction (qRT-PCR)  
iPSC-RPE and hESC-RPE ICB cells and human fetal RPE (fRPE, kindly provided by 
Lincoln Johnson (Center for the Study of Macular Degeneration, UCSB) and Dean Bok 
(Jules Stein Eye Institute, UCLA)) were thawed and plated on Matrigel and cultured for 
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30 days. fRPE were cultured using the medium and methods of Maminishkis et al. [27]. 
Cell lysates were collected using RLT Plus buffer with 1% β-mercaptoethanol and RNA 
was purified using Qiagen’s RNeasy Plus Kit (Qiagen, Limberg, Austria). 
Photomicrographs were taken at day 30. The iScript cDNA Synthesis Kit (BioRad, 
California, USA) was used to create 1µg of cDNA. Expression of genes of interest was 
evaluated for three separate enrichments, per line, and with internal triplicates, using 
the same TaqMan gene expression assays as cited in Croze et al., 2014 [28].  The probes 
analyzed were as follows: RPE-specific protein 65kDa (RPE65) Hs01071462_m1; 
bestrophin 1 (BEST1) Hs00188249_ml; retinaldehyde binding protein 1 (RLBP1) 
Hs00165632_ml; microphthalmia-associated transcription factor (MITF2) isoform 2 
AJD1S3G; premelanosome protein (PMEL) Hs00173854_m1; tyrosinase (TYR) 
Hs00165976_ml; paired box 6 (PAX6) Hs01088112_m1; marker of proliferation Ki-67 
(MKI67) Hs01032443_m1; zinc finger protein 42 (REX1) Hs01124465_m1; spalt-like 
transcription factor 4 (SALL4) Hs00360675_m1; microtubule-associated protein 2 
(MAP2) Hs00258900_m1; integrin, alpha 2 (ITGA2) Hs00158127_m1; 
platelet/endothelial cell adhesion molecule 1 (PECAM1) Hs00169777_m1; S100 
calcium binding protein A4 (S100A4) Hs00243202_m1; and housekeepers: eukaryotic 
translation initiation factor 2B, subunit 2 beta (EIF2B2) Hs00204540_m1; ubiquitin-
conjugating enzyme E2R 2 (UBE2R2) Hs00215107_m1; and small EDRK-rich factor 2 
(SERF2) Hs00428481_m1 (Life Technologies). The relative level of expression for each 
gene was determined by normalizing to the geometric mean of the housekeeping gene 
set using CFX Manager (Bio-Rad) and Excel software. Student’s t-test were run 
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comparing methods within each line, and then between two lines, same method, to 
determine statistical significance.  
Immunocytochemistry (ICC) 
 Passage 3 iPSC-RPE and hESC-RPE were seeded onto Matrigel-coated 8-
chambered slides. Thirty days after plating, the cells were washed with PBS and fixed 
with 4% paraformaldehyde in 0.1M sodium cacodylate buffer (pH 7.4) for 15 minutes at 
4°C. The fixed cells were then washed with PBS and blocked with PBS containing 5% 
bovine serum albumin (BSA) and 0.2% Triton X-100 for 1 hour at 4°C. The cells were 
then probed with primary antibodies against MITF (1:100, Abcam, Cambridge, MA, 
USA), orthodenticle homeobox 2 (OTX2) (1:4000, Millipore, Billerica, MA, USA), RPE65 
(1:100, Abcam), PMEL (1:100, Dako), zona occuldens 1 (ZO-1) (1:100, Life 
Technologies), or TRA1-81 (1:100, Millipore) in PBS with 5% BSA overnight at 4°C. 
Following 3 washes to remove the primary antibodies, cells were incubated with the 
appropriate Alexa Fluor conjugated secondary antibody (1:300, Life Technologies) for 1 
hour at 4°C, washed with PBS and mounted using Prolong Gold Anti-fade (Life 
Technologies).  Labeled cells were then washed with PBS and imaged using 
epifluorescent microscopy at 40X objective on a BX51 Olympus Microscope. 
Rod Outer Segment (ROS) Phagocytosis Assay 
 IPSC-RPE, hESC-RPE, and fRPE were cultured using the medium and methods of 
Maminishkis et al. [27]. ARPE19 cells (ATCC, Virginia, USA) were cultured in Dulbecco’s 
modified Eagle’s medium with nutrient mix F12 and sodium pyruvate (DMEM/F12, Life 
Technologies), supplemented with GlutaMAX-I (1X, Life Technologies), 10% FBS (Atlas 
Biologicals, Colorado, USA) and 15mM HEPES (Life Technologies). Human umbilical 
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vein endothelial cells (HUVEC, ATCC) were grown in endothelial cell growth medium 
with supplement mix (EGM, PromoCell, Heidelberg, Germany). All cells were plated in 
quadruplicate onto 0.1% gelatin-coated wells and cultured for 30 days. The ROS 
phagocytosis assays were performed according to the methods of Croze et al. 2014 [28]. 
The fRPE and ARPE19 cells serve as positive controls and the HUVEC line was used as a 
negative control. All experiments were normalized to a single ARPE19 experimental 
data set. Following this normalization, the fRPE ROS values were set to 100% within 
each individual experiment and percent difference from this condition was determined. 
The anti-αVβ5 condition had significantly lower internalization then ROS and ROS+IgG 
in every cell line, except for the negative control HUVECs (Data not shown, p≤0.05). 
Student’s t-tests were run to determine statistical significance. 
Pigment Epithelium Derived Factor (PEDF) Enzyme-Linked Immunosorbent Assay 
(ELISA) 
 Thawed ICB iPSC-RPE, hESC-RPE, and fRPE were grown on gelatin coated wells 
in medium described in Maminishkis et al., plus 0.5X Normocin (InvivoGen, California, 
USA) [27]. On day 30, media was collected following a 24 hour exposure to the cells. The 
amount of human PEDF was determined by ELISA according to the manufacturer’s 
instructions (BioProducts MD, LLC., Maryland, USA). All media volumes were kept 
constant and the growth area and volume were taken into consideration when 
calculating PEDF concentrations. Statistical significance was determined by an 
individual Student’s t-test between two conditions at a time. 
Results 
RPE morphology and pigmentation differ between iPSC lines and derivation methods 
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Cells were thawed after undergoing 14-day directed or SCAC differentiation, 
expansion to passage 2, and intermediate cryopreservation (Fig. 3A); then RPE 
morphology was assessed at passage 3. Notably, we began this study with five iPSC 
lines, however two lines (DF6 and OAT) yielded insufficient quantities of RPE for 
characterization when differentiated using the SCAC method (Supp. Table 1).  
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Figure 3. Morphology and degree of pigmentation in iPSC-RPE. (A) Schematic 
representation of 14-day directed (top) and spontaneous continuously adherent culture 
(SCAC, bottom) differentiation timelines. Phase contrast (B,D) and bright field (C,E) 
images of passage 3, day 30 DF4 iPSC-RPE derived by SCAC (B,C) or 14-day 
differentiation (D,E). (C) Black arrowheads indicate patches of cells lacking RPE 
morphology. Phase contrast (F,H) and bright field (G,I) images of passage 3, day 30 
DF19 iPSC-RPE derived by SCAC (F,G) or 14-day differentiation (H,I). Phase contrast 
(J,L) and bright field (K,M) images of passage 3, day 30 MyCell iPSC-RPE derived by 
SCAC (J,K) or 14-day differentiation (L,M). Scale bar=100µm.  
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We found DF4, DF19, and MyCell iPSC-RPE lines yielded pigmented cells with 
cuboidal morphology by day 30 using both differentiation methods, but with varying 
efficiency (Fig. 3B-M). Comparison of RPE within the same iPSC line showed differences 
in cell morphology and pigmentation depending on the method of derivation, which 
were especially apparent for DF4 iPSC-RPE. The 14-day-derived DF4 iPSC-RPE were 
noticeably less pigmented (Fig. 3E) when compared to DF4 iPSC-RPE derived by the 
SCAC method (Fig. 3C). Additionally, 14-day-derived DF4 iPSC-RPE yielded patches of 
cells lacking defined tight junctions (Fig. 3D, arrowheads). DF19 iPSC-RPE derived by 
the 14-day method appeared slightly less pigmented (Fig. 3I) when compared to SCAC-
derived DF19 iPSC-RPE (Fig. 3G), however cell morphology appeared normal (Fig. 3H) 
and similar to SCAC-derived DF19 iPSC-RPE (Fig. 3F). In contrast, 14-day-derived 
MyCell iPSC-RPE showed more uniform morphology (Fig. 3L) and appeared more 
pigmented (Fig. 3M) than SCAC-derived MyCell iPSC-RPE on day 30 (Fig. 3J, 3K).  
Comparing line by line for each method, all three SCAC-derived iPSC-RPE lines 
were similarly pigmented (Fig. 3C, 3G, 3K), however DF19 iPSC-RPE had the best 
morphology (Fig. 3F) compared to DF4 and MyCell iPSC-RPE (Fig. 3B, 3J), showing 
clearly defined tight junctions and more homogenous cell size. MyCell iPSC-RPE were 
the most pigmented of the 14-day-derived iPSC-RPE lines (Fig. 3M) and were 
comparable with DF19 derived by the same method in terms of typical RPE morphology 
(Fig. 3H, 3L). DF4 iPSC were the least efficient at generating RPE with mature 
morphology and pigmentation when derived using the 14-day method (Fig. 3D, 3E).  
Gene expression profiles change between iPSC-RPE lines and derivation methods 
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 RNA from ICBs of iPSC-RPE was isolated on day 30 post thaw at passage 3 and 
was subjected to qRT-PCR examining a range of RPE (Fig. 4A) and non-RPE transcripts 
(Supp. Fig. 1A,B). fRPE were also thawed and grown for 30 days as a positive control 
comparison. Mature RPE marker BEST1 displayed lower levels in the 14-day-derived 
DF4 and DF9 iPSC-RPE when compared to the SCAC-derived lines. 14-day-derived DF4 
iPSC-RPE had lower levels of RLBP1 from the DF4 SCAC line; however the 14-day-
derived DF19 line showed an increase in this visual cycle transcript compared to the 
DF19 SCAC line. 14-day-derived DF4 iPSC-RPE also exhibited a decrease in PMEL and 
TYR expression (pigmentation markers) from SCAC-derived DF4 iPSC-RPE. 14-day-
derived DF19 iPSC-RPE expressed less TYR than SCAC-derived DF19 iPSC-RPE. The 
Mycell iPSC-RPE line exhibited no significant differences between methods in RPE 
specific transcripts. However, PAX6, an immature RPE and neural retina marker was 
lower in 14-day-derived MyCell iSPC-RPE. RPE65 and MITF2 (specific RPE isoform) 
showed no changes between methods within lines (Fig. 4A).  
 14-day-derived DF4 iPSC-RPE exhibited statistically lower levels of BEST1, 
RLBP1, PMEL and TYR than the 14-day-derived DF19 iPSC-RPE (p≤0.05). 14-day-
derived DF4 iPSC-RPE also showed a statistical decrease in RPE65, BEST1, RLBP1, 
PMEL and TYR expression compared to 14-day-derived MyCell iPSC-RPE (p≤0.05). 14-
day-derived DF4 iPSC-RPE had increased levels of PAX6 compared to DF19 and Mycell 
iPSC-RPE within the 14-day-directed method (p≤0.01). Interestingly, RPE65 was 
increased in 14-day directed DF4 iPSC-RPE compared to 14-day directed DF19 iPSC-
RPE (p≤0.05). In addition, 14-day-derived DF19 iPSC-RPE showed decreased levels in 
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RPE65, BEST and an increase in RLBP1 when compared to 14-day derived MyCell iPSC-
RPE (Fig. 4A, p≤0.05).  
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Figure 4. Gene expression in iPSC-RPE compared between methods and to fRPE. (A) 
RPE specific, pigmentation and neural retina/immature RPE expression was analyzed 
after thaw at passage 3, 30 days post-plating. All data was normalized to geometric 
mean of three housekeeper mRNAs. Error bars represent ± SEM. *p≤0.05 **p≤0.01 
compared to same iPSC-RPE line, different method. n=3, separate enrichments for each 
line and method. 
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 There was only one statistical difference between the lines within the SCAC-
derived method. SCAC-derived DF4 iPSC-RPE had increased levels in TYR when 
compared to SCAC-derived MyCell iPSC-RPE (Fig. 4A, p≤0.01). Overall there was less 
variation between lines within the SCAC-derived method of differentiation. Within the 
14-day-directed differentiation, the DF4 iPSC-RPE exhibited lower amounts of several 
critical RPE specific transcripts and showed an increase in the neural retina marker, 
PAX6. The 14-day directed cells may be less mature than SCAC-directed RPE when 
assessing statistics of critical RPE transcripts. However, this might be expected since 
the time to enrichment is 14 days versus 90 days as in the SCAC method. To examine 
whether the 14-day directed iPSC-RPE lines can mature if given longer time in culture, 
14-day directed DF4 and DF19 iPSC-RPE cells were grown for 60 days following thaw. 
DF4 and DF19 lines were examined since they had the largest discrepancies in levels of 
RPE specific transcripts compared to the SCAC-directed method. RPE65 transcript 
levels, a mature RPE marker, were analyzed at 30 and 60 days post-thaw and a 
statistical increase of expression was examined for both 14-day directed DF4 and DF19 
iPSC-RPE (Fig 4B). 
 Expression levels of contaminate markers and hESC-RPE derived cells from each 
method are shown in Supplemental Figures 1 and 2. All contaminate levels for all lines 
and methods were below background. See Supplemental Figure 1 legend for positive 
control contaminate marker levels. 
Protein localization remains similar between lines and methods, with DF4 iPSC-RPE as 
the exception 
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Despite differences in morphology, pigmentation, and gene expression profiles, 
localization of RPE proteins appeared similar in all cell lines regardless of the 
differentiation method used, with the exception of 14-day derived DF4 iPSC-RPE. In all 
other cell lines, MITF and OTX2 transcription factors showed nuclear localization (Fig. 
5A, 5B). Similarly, PMEL and RPE65 were localized to the cytoplasm (Fig. 5C, 5D), as 
expected, and ZO-1, a marker for tight junctions, showed positive staining at the 
perimeter of the cell (Fig. 5E). Protein expression and localization in DF19 and MyCell 
iPSC-RPE derived by either the 14-day or SCAC methods were analogous, and both cell 
lines were comparable to hESC-RPE (Supp. Fig. 3) derived using the respective 
differentiation protocol. The SCAC-derived DF4 iPSC-RPE also exhibited expected 
protein localization, which was comparable to other SCAC-derived iPSC- and hESC-RPE 
lines. Notably, ZO-1 staining in DF4 iPSC-RPE and DF19 iPSC-RPE derived by the SCAC 
method showed increased presence of larger cells and/or cells with abnormal 
morphology (Fig. 5E, arrows). 
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Figure 5. Protein localization and expression in iPSC-RPE. Immunofluorescence images 
of (A) OTX2, (B) MITF, (C) PMEL, (D) RPE65, (E) ZO-1, and (F) TRA1-81 are shown for 
passage 3, day 30 DF4, DF19, and MyCell iPSC-RPE derived by SCAC or 14-day directed 
differentiation. (E) Arrows indicate SCAC-derived DF4 and DF19 iPSC-RPE with 
abnormal morphology (large cells) based on ZO-1 expression. White arrowheads 
indicate patches of 14-day-derived DF4 iPSC-RPE lacking tight junctions (ZO-1 
negative). Scale bar=50µm.  
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DF4 iPSC-RPE derived by the 14-day method showed abnormal non-nuclear 
staining of OTX2 and MITF (Fig. 5A, 5B). In some cells, ZO-1 was absent or localized to 
the cytoplasm (Fig. 5E, arrowheads), indicating a potential loss of junctional integrity, 
which has been previously observed in RPE cell lines after exposure to oxidative 
stressors [29] and EMT [30], and correlates with the poor morphology of these cells 
(Fig. 3C, arrowheads). Expression of PMEL and RPE65 localized as expected in 14-day-
derived DF4 iPSC-RPE (Fig. 5C, 5D), however only patches of cells stained positive for 
RPE65 while others were devoid of signal (Fig. 5D). These findings parallel results 
depicted in Figure 3, showing the capacity of DF4 iPSC to generate and propagate 
mature RPE using the 14-day method is limited. Importantly, none of the cell lines 
expressed TRA1-81, a marker for pluripotent cells, when derived by the SCAC or 14-day 
methods (Fig. 5F). 
Functional Comparison of SCAC and 14-day Differentiation Methods 
 RPE have numerous critical functions that maintain photoreceptor health [12]. 
To determine the functionality of the iPSC-RPE lines and elucidate any discrepancies 
between lines we performed two established tests to examine phagocytic abilities and 
PEDF secretion.  
 Phagocytosis was determined by internalization of FITC-labeled bovine-isolated 
ROS. Data were then calculated as a percent change from fRPE ROS treatment to 
statistically compare all lines and methods. Importantly, cells were also treated with a 
function blocking αVβ5 antibody, the critical integrin associated with phagocytosis in 
RPE. In all iPSC-RPE, fRPE and hESC-RPE lines, the anti-αVβ5 antibody significantly 
reduced phagocytosis compared to the ROS condition (Fig. 6A, p≤0.05). This 
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distinguished that the RPE were phagocytosing, not endocytosing ROS, and were using 
the same mechanism known in vivo [31]. DF4 and DF9 lines showed no differences in 
phagocytic abilities between SCAC and 14-day directed differentiation (Fig. 6A). 
However, the 14-day-derived MyCell iPSC-RPE line showed significantly more 
phagocytosis than the SCAC-derived MyCell line (Fig. 6A). There was no significant 
difference in phagocytosis between iPSC-RPE lines for either method. Fetal RPE were 
used as a positive control; many have published that their phagocytosis rate is low 
when compared to hESC-RPE, and the same phenomena was observed when compared 
to iPSC-RPE [20, 21, 28].   
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Figure 6. Functional analysis of iPSC-RPE lines and fRPE. (A) RPE phagocytosis of 
bovine photoreceptor outer segments (ROS) as determined by pixel density percent 
change of fRPE ROS condition. ROS condition displayed with αVβ5 functional blocking 
antibody analysis.  fRPE and HUVECs serve as positive and negative controls, 
respectively. All experiments are normalized to a single ARPE19 ROS experiment data 
set. 14-day-derived MyCell iPSC-RPE showed significantly more phagocytosis than 
SCAC-derived MyCell iPSC-RPE. All lines showed significantly decreased phagocytosis 
following anti- αvβ5 treatment. (B) ELISA analysis of PEDF. 14-day-derived DF4 iPSC-
RPE secreted a lower level of PEDF than SCAC-derived DF4 iPSC-RPE. Error bars 
represent ± SEM. *p≤0.05, n≥3, separate enrichments for all experiments. 
  61 
 IPSC-RPE were also compared to hESC-RPE differentiated using the same 
method. DF4 and MyCell SCAC-derived iPSC-RPE phagocytosed less than H9 hESC-RPE 
(Supp. Fig. 4A). However, MyCell 14-day-derived iPSC-RPE showed an increase in 
phagocytosis from 14-day-derived differentiated UCSF4 hESC-RPE (Supp. Fig. 4B). It is 
important to note that H9 hESC-RPE and UCSF4 hESC-RPE cannot be directly compared. 
Overall, it appeared that all iPSC-RPE lines, independent of method, were phagocytosing 
significantly more than the HUVEC negative control line and were doing so using the 
known in vivo mechanism. 
 To detect for PEDF secretion, an ELISA was performed on medium collected 
following a 24 hour exposure to each iPSC-RPE line and was compared to fRPE PEDF 
levels (Fig. 6B). DF4 iPSC-RPE created using the 14-day method secreted significantly 
lower amounts of PEDF than the SCAC-derived DF4 iPSC-RPE. DF19 and MyCell lines 
displayed no difference in secretion between methods. SCAC-derived DF4 iPSC-RPE line 
was significantly lower than SCAC DF19 and MyCell iPSC-RPE (p≤0.01).  PEDF secretion 
for the 14-day differentiated DF4 iPSC-RPE was significantly decreased compared to 
14-day-derived MyCell iPSC-RPE (p≤0.01). PEDF levels in all lines, independent of 
method, were significantly lower than fRPE PEDF secretion (p≤0.05). (SCAC-derived H9 
hESC-RPE secretion = 19.23±0.62ng/mm2 and 14-day-derived UCSF4 hESC-RPE levels = 
20.04±2.99 ng/mm2).   
Discussion 
As iPSC technology continues to broaden in application for regenerative studies 
and more iPSC-derived cellular products move toward the clinic, establishing release 
analyses to assess quality and minimize variability between lines will be essential. 
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Using a multitude of assays to examine RPE maturity and function, this study provides 
an extensive comparison between multiple iPSC-RPE lines derived by established 
methods. Our results showed that all three iPSC lines characterized in this study 
generated RPE using the SCAC and 14-day directed differentiation methods; however, 
differences were found between derivation methods within the same iPSC-RPE line. 
Further, we observed line-by-line variation when using the same method, which has 
been previously reported with RPE [13, 18, 32], and other cell types derived from iPSC 
[32-36]. Overall, independent of differentiation method, the DF19 and MyCell lines 
produced the highest quality iPSC-RPE as determined by morphology, expression of 
RPE-specific genes, and functional analyses, while the DF4 line was the least robust.  
A comparison to fRPE and hESC-RPE revealed iPSC-RPE derived by both 
methods secreted lower levels of PEDF and expressed lower levels of RPE genes related 
to visual cycle function (RPE65 and CRALBP), epithelial barrier function (BEST1), and 
RPE lineage (MITF2). These results are in agreement with other studies showing iPSC 
are not as efficient in generating RPE [20, 37, 38] and may take slightly longer to 
differentiate to retinal lineages than hESC [35, 39]. In contrast, however, iPSC-RPE 
derived by both methods expressed pigment-specific genes (PMEL and TYR) 
comparable to hESC-RPE (with some exceptions in 14-day-derived DF4 iPSC-RPE) and 
were able to outperform fRPE ROS phagocytosis in vitro. These discrepancies further 
underscore the need for standardized assays that accurately test RPE quality between 
lines. Since DF4 iPSC-RPE derived by the 14-day method showed the poorest 
performance in all assays except ROS phagocytosis, other analyses such as PEDF 
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secretion and expression of RPE function markers may be better indicative of a true 
RPE lineage.  
 Based on low expression levels of RPE65 in 14-day RPE (iPSC- and hESC-
derived) compared to SCAC-derived cells, it is plausible that the 14-day RPE are not of 
lower quality, but are simply just immature, which may account for some of the 
differences we observed between differentiation methods. As more groups, including 
our own, develop protocols to push pluripotent cells toward RPE and other lineages in 
less time, it will be important to keep this question in mind - how fast can we speed up 
development in vitro? We showed that maturing 14-day-derived DF4 and DF19 iPSC-
RPE for an additional 30 days significantly boosts expression of RPE65 (Fig. 4B), which 
is a critical regulator of visual cycle function, indicating longer time in culture may be 
essential for cells to develop properly. Importantly, we found all five iPSC lines 
originally used for this study could be induced to differentiate to RPE using the 14-day 
protocol, albeit with varying efficiencies, while two lines were unable to generate 
usable quantities of RPE with SCAC differentiation. These results indicate that some 
iPSC lines may require a more directed approach to produce enough cells for 
characterization and could be a case for using directed methods over a longer, 
spontaneous approach. 
The original source of donor cells and the method of reprogramming are 
possible explanations for the differences seen in the quality of RPE differentiation 
between iPSC lines. MyCell iPSC were derived from T cells, while DF4 and DF19 iPSC 
were derived from foreskin fibroblasts [25]. Previous studies have shown RPE and 
neuroretinal cell types can be differentiated from T cell- and fibroblast-derived iPSC 
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[18, 20, 35, 38-42]; however characterized RPE have not been compared based on 
somatic cell origin. We found that DF19 and MyCell iPSC were broadly comparable in 
RPE derivation capability; thus it is unlikely, at least for the purposes of this study, that 
identity of the source cells contributed considerably to the ability of iPSC to 
differentiate to RPE. Further, DF4, DF19, and DF6 iPSC, all derived from the same 
foreskin fibroblast line [2, 25], showed substantial differences in RPE generation 
capacity. DF6 iPSC were unable to generate enough RPE for characterization using SCAC 
without contaminating cell types in the culture. This suggests that the method of 
reprogramming to iPSC may be more strongly contributing to RPE differentiation 
variability between lines. All three foreskin fibroblast-derived iPSC lines (DF4, DF19 
and DF6) were reprogrammed using EBV-based episomal systems; however, different 
transgene arrangements and combinations of episomal vectors were used to induce 
pluripotency for each line [25]. It has been suggested that maintaining a balance 
between transgene expression levels is crucial for efficient reprogramming [43]. Thus it 
is possible that DF4 and DF6 iPSC lines may not be efficiently reprogrammed compared 
to DF19, and as a consequence, may have more limited differentiation and expansion 
capacity as RPE. 
 In summary, these data present a comparison between RPE differentiation 
methods for multiple iPSC lines, showing variability in RPE derivation capacity not only 
between methods, but also between iPSC lines within the same method. Furthermore, 
we showed that poorly differentiated iPSC-RPE (DF4) still performed ROS functional 
assays, that 14-day-derived RPE could be matured in culture for 30 days to improve 
RPE-specific marker expression, and that some iPSC lines may require directed 
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differentiation to generate enough RPE for characterization. As iPSC-RPE become more 
clinically applicable, these results have potentially important implications for 
developing standardized release assays, optimizing iPSC reprogramming methods, and 
developing superior iPSC lines as well as culture methods to use for patient therapy.    
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Introduction 
 Human embryonic stem cells (hESC) offer a potentially unlimited supply of cells 
for emerging cell-based therapies. Unfortunately, the process of deriving distinct cell 
types can be time consuming and expensive. Furthermore, differentiated cells typically 
have a finite lifespan and can only be passaged a limited number of times. Expanding 
the propagation potential of stem cell-derived cells would be extremely useful for 
transplantation procedures and drug screening efforts. 
 Clinical trials are currently under way using hESC derived retinal pigmented 
epithelial cells (hESC-RPE) as a treatment for age related macular degeneration (AMD) 
[1, 2]. In the developed world, AMD is the leading cause of blindness in the elderly with 
over 7.2 million people afflicted in the US alone [3, 4]. AMD is a progressive disorder 
that eventually results in RPE cell death, photoreceptor death, and profound loss of 
central vision. It is generally agreed that AMD pathology is primarily linked to the 
dysfunction and death of the RPE, which acts to support and maintain the 
photoreceptors. When the RPE degenerates, the photoreceptors can no longer function 
and they eventually die [5, 6]. There are two clinically recognized forms of disease, 
exudative (wet) AMD and atrophic (dry) AMD. The neovascular genesis component of 
wet AMD can be successfully managed using anti-vascular endothelial growth factor 
drugs such as Lucentis, Avastin or Eylea [7]. However, these drugs do not act to inhibit 
the underlying RPE degeneration and patients with wet AMD can progress to more 
advanced stages of atrophic AMD characterized by macular regions devoid of RPE and 
photoreceptors [8, 9]. Outside of a vitamin cocktail which can only slow the progression 
  71 
of AMD in 25% of patients taking the supplement, there is no effective treatment for dry 
AMD [10, 11]. 
 Both hESC-RPE and induced pluripotent stem cell derived RPE (iPSC-RPE) [12] 
are being developed for AMD therapies by multiple groups, using either cell 
suspensions or differentiated monolayers on scaffolds [13]. The current preferred 
derivation process for RPE follows a spontaneous differentiation protocol involving the 
removal of fibroblastic growth factor 2 (FGF2) in continuously adherent cultures of 
pluripotent stem cells [1, 14]. This method can take up to 100 days before enrichment 
of the pigmented population followed by several months of additional culture to obtain 
relatively homogeneous, mature RPE ready for transplantation. hESC-RPE, iPSC-RPE 
and fetal RPE are passaged every 30 days and can only be maintained in culture for five 
to six passages before the cells display abnormal characteristics and are thought to 
undergo an epithelial-to-mesenchymal transition (EMT) [15-18]. Some reports have 
claimed an even more limited passage potential for iPSC-RPE, finding only one passage 
following enrichment was possible [19].  These late passage cells lose their pigmented, 
cobblestone morphology and appear more fibroblastic, and often senesce and die.  
Senescence in cultured primary somatic cells is commonly observed as telomeres 
shorten and the Hayflick limit is reached [20].  
 To attempt to overcome this passage limitation, we examined the involvement of 
Rho-associated, coiled-coil protein kinase (ROCK) in hESC-RPE and iPSC-RPE culture. 
Two distinct ROCK isoforms, ROCK1 and ROCK2, are activated by RHOA GTPase and 
initiate signal transduction cascades to modulate central cell functions, including 
proliferation, apoptosis, cytoskeletal rearrangements, and migration [21-23]. The 
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RHOA/ROCK pathway has been studied extensively for its downstream effects on stress 
fiber formation [24, 25] and actin filament stabilization [21, 26]. ROCK inhibition using 
synthetic compounds is currently being tested in clinical trials for pulmonary 
hypertension treatments with positive animal model results [23, 27, 28]. Current 
research suggests increasing roles for ROCK inhibitors, including ROCK1/2 inhibitor Y-
27632, in regulating various cell processes [23, 29-31]. Previous studies have showed 
ROCK inhibition increased passage abilities of certain epithelial cell types [32-36], as 
well as the clonability of hESC [37, 38]. We have previously shown the beneficial effects 
of Y-27632 treatment following initial enrichment of RPE during directed 
differentiation from hESC [39].  
 Here we report that inhibiting ROCK1/2 with Y-27632 allows extended passage 
of hESC-RPE. Importantly, the resulting hESC-RPE cells maintain proper gene 
expression, protein localization, function, and karyotype. We also show evidence that 
iPSC-RPE extended passage is possible following ROCK1/2 inhibition as well. The 
simple culture methods described here allow a much greater yield of hESC-RPE and 
iPSC-RPE and can provide abundant cells for disease modeling, drug screening and 
further development of cellular therapies. 
Materials and Methods 
Cell Culture 
Pluripotent Stem Cell Culture 
 H9 hESC were obtained from the WiCell Research Institute in Madison, WI. 
Vector free iPSC lines, DF 4.9, DF 19.11 and Mycell were obtained from David Gamm 
and James Thomson (University of Wisconsin, Cellular Dynamics International). hESC 
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and iPSC were maintained in mTeSR1 medium (STEMCELL Technologies, Vancouver, 
Canada) and grown on Matrigel coated plates (1:100 dilution, BD Biosciences, San Jose, 
CA, USA) at 37°C 5% CO2 under normoxic conditions. 
Continuously Adherent Retinal Pigmented Epithelium Differentiation and Enrichment 
 H9 hESC and iPSC were passaged onto Matrigel coated plates and allowed to 
overgrow for 8-14 days. mTeSR1 medium was then changed to X-VIVO 10 (Lonza, Basal, 
Switzerland), after which the X-VIVO 10 medium was changed every other day. X-VIVO 
10 is a xeno-free medium that has been used with cells designed for therapeutic use and 
increases the efficiency of RPE differentiation [40]. Pigmented cells typically appeared 
after 4-6 weeks.  After 90 days in X-VIVO 10, non-pigmented cells were removed via 
mechanical dissection and the remaining, mostly pigmented cells, were incubated with 
TrypLE Express (Life Technologies, Grand Island, NY, USA) for 5 minutes at 37°C. The 
resulting hESC-RPE or iPSC-RPE enriched cell suspension was passed through a 30µm 
strainer and replated on Matrigel coated plates using X-VIVO 10. Enriched RPE cultures 
were maintained at 5% CO2 and 37°C in X-VIVO 10. The medium was changed every 
other day. Every 30 days the cells were harvested using TrypLE Express and replated at 
a density of 100,000 cells/cm2. All passage 2 cells used in comparison to passage 13 Y-
27632 treated cells were cultured following this method. 
Extended Passage Protocol of hESC-RPE and iPSC-RPE 
 Directly following enrichment, hESC-RPE or iPSC-RPE were plated into four 
Matrigel coated wells at 25,000 cells/cm2 in X-VIVO 10. Two wells were treated with Y-
27632 (10µM, Tocris Bioscience, Bristol, UK) and the other two received an equal 
volume of water, as a control. One day post confluence (~4-5 days), one Y-27632 
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treated well and one control well were passaged and seeded again at 25,000 cells/cm2. 
Passaging continued in this fashion until cells failed to reach confluence. The two wells 
not undergoing passaging continued to be supplemented with 10µM Y-27632 or water 
for 14 days. On day 30 RNA was harvested and images were taken on the Olympus 
CKX41 (Olympus, Center Valley, PA, USA). Passage 13 hESC-RPE used in all experiments 
were derived using this protocol. The extended passage experiment was performed 
with seven separate enrichment cultures of H9 hESC-RPE and three enrichments per 
iPSC-RPE line. Each ‘n’ represents a unique enrichment from a distinct H9 culture for 
every experiment. 
MTT Assay 
 To determine the effect of ROCK inhibition on hESC-RPE cell proliferation, cells 
were plated into 96 well plates in X-VIVO 10 and allowed to attach for 2 hours. hESC-
RPE are extremely adherent and we observe that following only 2 hours, most of the 
cells have attached. The medium was then removed and replaced with fresh X-VIVO 10 
with or without 10µM Y-27632. The media were changed every two days for the 
duration of the experiment with continual Y-27632 supplementation. Cell proliferation 
was assessed by determining the number of viable cells using a MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay according to supplier 
instructions (Life Technologies, Carlsbad, CA, USA).  
Quantitative Real Time PCR (QRT-PCR) 
Total RNA was isolated using the Qiagen RNeasy Plus Extraction Kit (Qiagen, 
Valencia, CA, USA) and cDNA was generated using an iScript cDNA synthesis kit 
(BioRad). The extent of expression of genes of interest was then evaluated in triplicate 
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for using the following TaqMan gene expression assays (Life Technologies): RPE 
specific protein 65kDa (RPE65) Hs01071462_m1; bestrophin 1 (BEST1) 
Hs00188249_ml; retinaldehyde binding protein 1 (RLBP1) Hs00165632_ml; 
microphthalmia-associated transcription factor (MITF) isoform 2 AJD1S3G; 
premelanosome protein (PMEL) Hs00173854_m1; tyrosinase related protein 1 
(TYRP1) Hs00167051_m1; tyrosinase (TYR) Hs00165976_ml; paired box 6 (PAX6) 
Hs01088112_m1; marker of proliferation Ki-67 (MKI67) Hs01032443_m1; zinc finger 
protein 42 (REX1) Hs01124465_m1; spalt-like transcription factor 4 (SALL4) 
Hs00360675_m1; microtubule-associated protein 2 (MAP2) Hs00258900_m1; integrin, 
alpha 2 (ITGA2) Hs00158127_m1; platelet/endothelial cell adhesion molecule 1 
(PECAM1) Hs00169777_m1; S100 calcium binding protein A4 (S100A4) 
Hs00243202_m1; and housekeepers: eukaryotic translation initiation factor 2B, subunit 
2 beta (EIF2B2) Hs00204540_m1; ubiquitin-conjugating enzyme E2R 2 (UBE2R2) 
Hs00215107_m1; and small EDRK-rich factor 2 (SERF2) Hs00428481_m1 (Life 
Technologies). The relative level of expression for each gene was determined by 
normalizing to the geometric mean of the housekeeping gene set using CFX Manager 
(Bio-Rad) and Excel software. 
Immunocytochemistry (ICC) 
 Passage 2 hESC-RPE and passage 13 Y-27632 maintained hESC-RPE were seeded 
onto Matrigel coated 8-chambered slides at 100,000 cells/cm2. The passage 13 hESC-
RPE were treated with 10µM Y-27632 for 14 days in medium described in Maminishkis 
et al. [41]. Forty-five days after plating, the cells were washed with phosphate-buffered 
saline (PBS, Life Technologies) and fixed with 4% paraformaldehyde in 0.1M sodium 
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cacodylate buffer (pH 7.4) for 7 minutes at 4°C. The fixed cells were then washed with 
PBS and blocked with PBS containing 5% bovine serum albumin (BSA) and 0.2% Triton 
X-100 for 1 hour at 4°C. The cells were then probed with primary antibodies against 
MITFC5 (1:1000, Abcam, Cambridge, MA, USA), orthodenticle homeobox 2 (OTX2) 
(1:4000 Millipore, Billerica, MA, USA), RPE65 (1:100, Abcam), BEST1 (1:100, Abcam), 
PMEL (1:100, Abcam), tight junction protein ZO-1 (TJP1) (1:100, Life Technologies), or 
MKI67 (1:1000, Abcam), in PBS with 5% BSA overnight at 4°C. Following 3 washes to 
remove the primary antibodies, they were incubated with appropriate Alexa Fluor 
conjugated secondary antibody (1:300, Life Technologies) for 1 hour at 4°C. Following 
the incubation with secondary antibody, cellular DNA was labeled by the addition of 
Hoescht (2µg/ml, Life Technologies) to the medium for 5 minutes at room temperature. 
The labeled cells were then washed with PBS and mounted with Prolong Gold Anti-fade 
and imaged using epifluorescent microscopy at 40X objective on a BX51 Olympus 
Microscopy. For both passages, five enrichments of hESC-RPE were probed with this 
panel of primary antibodies. 
Karyotype analysis 
 Karyotyping of passage two and passage 13 hESC-RPE, from the same 
enrichment, was performed by Cell Line Genetics. Cells were analyzed prior to reaching 
confluence. 
Rod Outer Segment  (ROS) Phagocytosis Assay 
 hESC-RPE and human fetal RPE (fRPE, kindly provided by Lincoln Johnson 
(Center for the Study of Macular Degeneration, UCSB) and Dean Bok  (Jules Stein Eye 
Institute, UCLA)) were cultured using the medium and methods of Maminishkis et al. 
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[41]. ARPE19 cells were cultured in Dulbecco’s modified eagle medium with nutrient 
mix F12 and sodium pyruvate (DMEM/F12, Life Technologies), supplemented with 
GlutaMAXI (1X, Life Technologies), 10% FBS (Atlas Biologicals) and 15mM HEPES (Life 
Technologies). Human umbilical vein endothelial cells (HUVEC) were grown in 
endothelial cell growth medium with supplement mix (EGM, PromoCell, Heidelberg, 
Germany). All cells were plated in quadruplicate at 100,000 cells/cm2 onto 0.1% 
gelatin-coated wells and cultured for 30 days. hESC-RPE passage 13 were treated with 
10µM Y-27632 for 14 days. 
 Rod outer segments (ROS) were isolated from bovine retinas [42] (Sierra for 
Medical Science, Whittier, CA, USA) and fluorescently labeled with FluoReporter FITC 
Protein Labeling Kit (Life Technologies). The cultured cells were treated with or 
without αVβ5 function blocking antibody (62.5µg/ml, Abcam) or IgG (62.5µg/ml 
Abcam) isotype control for 30 minutes at 37°C 5% CO2. Following the initial antibody 
incubation, the cells were challenged with 1x106 FITC-ROS/well for 5 hours at 37°C 5% 
CO2 [39, 43]  in media supplemented with a fresh aliquot of antibody. After ROS 
incubation, the wells were washed 6X with PBS and then 0.4% trypan blue was added 
for 20 minutes to quench any fluorescence originating from residual extracellular ROS. 
Each well was imaged using epifluorescent microscopy and integrated pixel density of 
photomicrographs were generated with Image J software (National Institute of Health, 
Bethesda, MD, USA) using a rolling pixel radius of 50. The phagocytosis assay was 
performed with three independent enrichments of hESC-RPE. The fRPE and ARPE19 
cells serve as positive controls and the HUVEC line was used as a negative control. All 
experiments were normalized to a single ARPE19 ROS experimental data set. 
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Pigment Epithelium Derived Factor (PEDF) and Vascular Endothelial Growth Factor 
(VEGF) Enzyme-Linked Immunosorbent Assay (ELISA) 
 Passage two hESC-RPE and passage 13 Y-27632 treated hESC-RPE were grown 
on Matrigel coated 0.45µm HA inserts (0.6cm2, Millipore) seeded at 100,000 cells/cm2 
in medium described in Maminishkis et al. [41]. The hESC-RPE passage 13 cells were 
-27632 for 14 days. On day 30, media was collected from both the 
apical and basal chambers following a 72 hour exposure to the cells. The amount of 
pigment epithelium derived factor (PEDF) and vascular endothelial growth factor 
(VEGFA) in the basal and apical compartments were determined by ELISA according to 
the manufacturer’s instructions (PEDF: BioProducts MD, LLC., Middletown, MD, USA; 
VEGFA: Life Technologies). All media volumes were kept constant and the growth area 
and volume were taken into consideration when calculating data. 
Agilent Whole Human Genome Microarray 
 hESC-RPE were cultured following the extended passage protocol. At passage 5, 
control and Y-27632 lysates were collected two days after plating, prior to reaching 
confluence. RNA from four separate biological replicates was isolated using the Qiagen 
miRNeasy Kit (Qiagen) for each treatment group. Global transcriptome analysis was 
performed with the Agilent Whole Human Genome 4 × 44K in situ oligonucleotide array 
platform (G4112F, Agilent Technologies, Inc., Santa Clara, CA, USA) using the reagents 
and methods of the manufacturer and a 2-color experimental design, pairing the control 
and Y-27632 samples. After background and Lowess correction, the 200 replicate probe 
sets were averaged and the entire array data set was quantile normalized. Array data 
are reported as normalized net intensity levels. 
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Results 
ROCK inhibition allows extended passage of hESC-RPE and iPSC-RPE 
 hESC-RPE or iPSC-RPE can typically only be passaged five to six times before 
undergoing a switch in phenotype suggestive of an epithelial-to-mesenchymal 
transition (EMT) and eventually senescing [15-18]. We sought to determine if inhibition 
of the Rho kinases, ROCK1 and ROCK2, could extend the effective passaging of hESC-
RPE and iPSC-RPE. To test the role of ROCK1/2 in this process, the synthetic compound, 
Y-27632, which is a competitive inhibitor of the ATP binding domain of both ROCK1 
and ROCK2 isoforms [23], was added to the culture medium, and cells were 
continuously passaged, plating at a fourth of the usual seeding density. For each 
passage, a portion of cells were grown for 30 days to allow them to mature and reach 
confluence, with removal of the ROCK inhibitor at day 14. Phase contrast images of the 
resulting cultures are shown in Figure 7. In contrast to untreated hESC-RPE, which 
underwent an EMT and failed to become confluent following five passages, Y-27632 
treated cells were able to assume their typical RPE cobblestone morphology up to 
passage 14. However, after 15 passages, patches of larger cells displaying a 
mesenchymal morphology (examples shown by arrows) were intermixed with areas of 
cells with epithelial morphology. By passage 18, cells failed to reach confluence 
following 30 days in culture and never regained the typical RPE morphology. All iPSC-
RPE lines acted in a similar fashion as hESC-RPE, but were not passaged beyond 
passage 13 (images not shown). Brightfield images of control passage 2 and Y-27632 
treated passage 13 hESC-RPE, depicted in Supplemental Figure 5, show similar 
pigmentation patterns.  
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Figure 7. Effect of ROCK inhibition on hESC-RPE passage. Control hESC-RPE and Y-
27632 treated hESC-RPE were serially passaged and cultured as detailed in Methods. 
Phase contrast images are shown of control and Y-27632-treated hESC-RPE, with 
passage number indicated in the upper right. All images were collected on day 30. 
Images are from a single experiment that is representative of nine experiments. Arrows 
indicate examples of cells with mesenchymal-like phenotype at passage 16, 17 and 18. 
Seeding density: 25,000 cells/cm2. Scale bar=100µm.  
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 To determine the effect of Y-27632 on the rate of proliferation cell counts were 
taken at each passage as hESC-RPE and iPSC-RPE underwent the extended passage 
protocol. Cells treated with Y-27632 showed a substantial increase in population 
doublings, allowing an average of 30 doublings compared to only 9 doublings in control 
cultures for both hESC-RPE and iPSC-RPE (Fig. 8A, B). In the presence of the ROCK 
inhibitor, cell numbers increase exponentially, with an average doubling time of 2.4 
days, whereas the control doubling time was significantly longer with an average of 3.8 
days, for hESC-RPE. There was some line to line variation in iPSC-RPE; however the 
average Y-27632 treated cell doubling time was 2.1 days compared to 3.6 days in 
control cells. All control cultures could not be propagated beyond 5 passages, 
suggesting that they had senesced. 
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Figure 8. ROCK inhibition affects hESC-RPE proliferation. (A) Population doubling (PD) 
is plotted versus time in cultures with and without addition of Y-27632. Each point 
represents a passage, n=5. PD=log2(number of cells counted at time of passage/number 
of cells plated) (B) Population doubling of three iPSC-RPE lines throughout the 
extended passage protocol. n=3 per line. (C) Passage 4 hESC-RPE grown in the presence 
or absence of Y-27632 and cell number was quantified by measuring MTT reduction. 
Error bars represent ± SEM. *p≤0.05 **p≤0.01 compared to control for the same time 
point. n=3 (same enrichment).  
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 In addition to monitoring cell expansion at the time of each passage, over 
numerous passages, cell proliferation was measured more directly within a single 
passage. Similar effects of Y-27632 on hESC-RPE growth rate were observed when the 
number of living cells within a single passage was monitored as a function of time using 
a MTT assay (Fig. 8C). When passage 4 hESC-RPE were grown in the continual presence 
or absence of Y-27632,  a significant increase in the number of cells was detected by 10 
days in the Y-27632 treated cells which persisted to at least day 30. Both control and Y-
27632 treated passage 4 cells retained RPE morphology at day 30; however the 
characteristics of these particular cells at higher passages was not examined. This 
experiment shows that ROCK inhibition speeds up the rate of proliferation of hESC-RPE.   
Gene expression during extended passage of hESC-RPE 
 In an effort to assess the effects of Y-27632 on gene expression we determined 
the relative amounts of a select set of RPE and non-RPE marker transcripts. As shown in 
Figure 9, control hESC-RPE showed a decrease in the abundance of  RPE RNAs (RPE65, 
BEST1 RLBP1, and MITF) as a function of passage, with significant differences being 
observed at passage 5 (Fig. 9). Interestingly, levels of pigment related mRNAs, PMEL, 
TYRP1, and TYR, remained constant in untreated hESC-RPE. PAX6, a neural retina and 
immature RPE marker, increased over passage, but not significantly. In contrast, in Y-
27632 treated hESC-RPE, all seven RPE marker RNA levels remained relatively stable 
over the course of 13 passages, and PAX6 mRNA levels did not increase. We believe that 
the larger error bars for several control passage 3 and passage 5 transcripts is due to 
the mixed population of cells arising within the well as the RPE begin to undergo EMT. 
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 In addition, although Y-27632 treatment preserves the mitotic potential of hESC-
RPE, there is no evidence for increased expression of MKI67, a marker of mitosis, in 
confluent 30 day old cultures of Y-27632 treated cells relative to that seen with 
untreated cells. This would imply that while cells proliferate more rapidly in the 
presence of Y-27632 (Fig. 8), the effects of Y-27632 are not lasting (Fig. 9). After 
removal of ROCK inhibition, cells reach confluence and exit from the cell cycle.  
We also examined markers for pluripotency, and potential contaminating or 
transdifferentiated cell types. The level of the pluripotent mRNAs, REX1 and SALL4, 
remained negligible with extended passage, as did the neuronal marker MAP2, the 
smooth muscle marker ITGA2, the endothelial marker PECAM, and the fibroblastic 
marker S100A4. (See figure legend for positive control cell values for non-RPE gene 
markers). 
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Figure 9. Gene expression in extended passage hESC-RPE. RPE specific, pigmentation, 
neural retina/immature RPE, cell cycle, pluripotent and non-RPE gene expression was 
analyzed as a function of passage at 30 days post-plating. All data was normalized to 
geometric mean of three housekeeper mRNAs. Positive control cell values for non-RPE 
genes: H9 hESC, Rex 1 (4.09±0.09), Sall4 (10.93±0.45); SH-SY5Y, MAP2 (0.78±0.29); 
SMC, ITGA2 (2.02±0.24); HUVEC, PECAM (15.7±0.53); Hs27, S100A4 (20.13±1.09).  
Error bars represent ± SEM. *p≤0.05 **p≤0.01 compared to passage one within the 
same treatment group. n=3.  
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Protein expression and localization during extended passage of hESC-RPE 
 To assess whether there were any gross differences in protein localization 
between differentiated cultures of Y-27632 treated, extended passage cells versus 
minimally passaged control cells, 30 day cultures of each condition were evaluated 
using immunocytochemistry. Cells were probed with antibodies directed against the 
RPE marker proteins MITF, OTX2, RPE65, BEST1, PMEL, and ZO-1 (TJP1) as well as an 
antibody against the mitosis associated antigen, MK167 (Fig. 10). In all cases the 
pattern of protein localization was indistinguishable between control cells at passage 2 
and Y-27632 treated cells at passage 13.  The mature RPE markers BEST1 and RPE65 
were both localized to the cytoplasm with additional localization of BEST1 to the 
plasma membrane being evident in passage 2.  The pigmentation associated protein 
PMEL was found to be co-localized with distinct melanosomes and the tight junction 
protein ZO-1 (TJP1) to cell borders. Consistent with the lack of evidence for the 
presence of MKI67 mRNA in 30 day control passage 2 or Y-27632 treated passage 13 
cells, no MIK67 immunoreactivity was detected. 
 Normal chromosomal arrangement was observed following karyotype analysis 
of control passage 2 and Y-27632 treated passage 13 cells (Supp. Fig. 6). 
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Figure 10. Protein expression and localization in extended passage hESC-RPE. Control 
passage 2 (left panel) and Y-27632 treated passage 13 (right panel) cells were stained 
for RPE markers and a mitotic marker after reaching confluence at day 30. Scale 
bars=100µm. Images shown are representatives of four experiments for each passage. 
Primary antibody stain is shown in left column and merged image with Hoescht (blue) 
is depicted in right column. 
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Functional analysis of extended passage hESC-RPE 
 The diurnal phagocytosis of photoreceptor outer segments, the apical secretion 
of PEDF, and basal VEGF secretion are critical RPE functions [44]. To examine these 
functions in extended passage hESC-RPE treated with the ROCK inhibitor, phagocytosis 
assays and ELISAs were performed. For the phagocytosis assays, hESC-RPE passage 2 
and hESC-RPE passage 13 cells, as well as negative and positive control cells were 
challenged with FITC labeled bovine rod outer segments (ROS) and the extent ROS 
uptake was measured using quantitative immunofluorescence microscopy. Passage 13 
Y-27632 treated hESC-RPE showed levels of phagocytosis similar to that seen in 
passage 2 control cells (Fig. 11A). To test whether phagocytosis occurred through the 
receptor-dependent mechanism utilized by RPE in vivo, cells were incubated with an 
integrin αVβ5 function blocking antibody prior to challenging with FITC labeled ROS. 
This integrin has been shown to be important for RPE phagocytosis [45]. There was a 
significant decrease in the amount of ROS internalization compared to IgG control 
treated cells (*p≤0.05) for fRPE, hESC-RPE passage 2 and hESC-RPE passage 13 cells 
after αVβ5 activity was blocked. This showed that phagocytosis requires the same 
integrin receptor after extended passage, and that passage 13 hESC-RPE retain normal 
phagocytosis activity. 
 For the determination of apical and basal growth factor secretion, media was 
collected from the inner and outer chambers of transwell hESC-RPE cultures and the 
amount of the PEDF and VEGF in the two media compartments was quantified. There 
was no significant difference for either apical or basal PEDF release between passage 2 
and passage 13 hESC-RPE (Fig. 11B).  The amount of basal VEGF secretion also 
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remained unchanged following extended passage in the presence of Y-27632, however 
there was 2-fold decrease in amount the apical VEGF in the passage 13 cultures 
compared to passage 2, but this did not reach significance (Fig. 11C).  
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Figure 11. Function of extended passage hESC-RPE. (A) RPE phagocytosis of bovine 
photoreceptor outer segments, as determined by pixel density analysis of 
photomicrographs, is shown.  fRPE and HUVECs serve as positive and negative controls, 
respectively. All experiments are normalized to a single ARPE19 ROS experiment data 
set. Isotype matched IgG was added as a negative control for the αVβ5 function blocking 
antibody. (B, C) ELISA analysis of PEDF and VEGF. Polarized hESC-RPE showed a higher 
level of apical PEDF and basal VEGF secretion, consistent between passages. Error bars 
represent ± SEM. *p≤0.05 **p≤0.01 (A) compared to samples treated with anti-αVβ5 (B, 
C) compared to secretion from opposite cell side. n=3 for all experiments.  
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ROCK inhibition affects transcript levels within many cell pathways 
 ROCK is known to be involved in numerous pathways within the cell, but its 
effect on gene transcription has not been fully examined. To gain more insight into how 
ROCK inhibition allows for extended passage of hESC-RPE, we assessed the global 
transcription patterns using cDNA microarray analysis in passage 5 control and Y-
27632 treated cells, two days post-plating. Microarray analysis revealed that around 
12,200 probes had above background signals. From those, just over 700 transcripts had 
at least a 1.5 fold change in each pairwise comparison and an average fold change of 
two or greater for all experiments. Three hundred and sixty nine genes decreased after 
treatment and 356 increased. 
 Our microarray data reiterates the published literature that ROCK plays a role in 
several different pathways that all could contribute to the ability of hESC-RPE to 
undergo extended passage (Table 1) [22, 26, 46, 47].  Table 1 summarizes the 
microarray data using a pathway centric organization based on the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) pathways containing ROCK. These pathways include: 
Actin Cytoskeleton Rearrangements, Adherens Junctions, Tight Junctions, Cell Adhesion 
Molecules, ECM Receptor Interactions/Focal Adhesions, Vascular Smooth Muscle 
Contraction, Axon Guidance, Chemokine Guidance, HIPPO Signaling, TGFβ Signaling, 
Wnt Signaling and the Cell Cycle. This analysis reveals a decreased expression of genes 
encoding proteins involved in tight junctions, cell adhesion molecules, ECM-receptor 
interactions, and focal adhesion, at day two, prior to cell confluence, following ROCK 
inhibition. In addition, examination of the HIPPO, TGFβ and Wnt signaling pathways 
showed lower levels of transcripts encoding key ligands as a result of ROCK inhibition. 
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No changes in SMADs were detected, however they are activated through 
phosphorylation, therefore more work is needed to uncover whether ROCK inhibition 
affects SMAD function. In addition, transcripts tied to progression through the cell cycle 
increased substantially after Y-27632 treatment. These data were also analyzed using 
the gene ontology enrichment analysis software DAVID [48, 49]. This analysis revealed 
several significant gene groups, many of which overlap the KEGG pathway analysis 
(Supp. Fig. 7).   
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Table 1. Changes in gene expression resulting from ROCK inhibition.  Microarray data 
comparing gene expression differences between control and Y-27632 treated hESC-RPE 
at day two passage five. The KEGG pathways containing ROCK and those affected by Y-
27632 addition are represented. Control and Y-27632 numerical values on the left 
represent the mean quantile normalized data of four biological replicates. Color coded 
ratio on the right represents log2(Y-27632/Control), 1=2 fold change. n=4. GEO link: 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=kxynoswinzslrgj&acc=GSE566
18 
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Discussion 
 RPE were first noted in differentiated hESC cultures in 2001 [50] and then 
expanded and characterized in a landmark paper by Klimanskaya et al. in 2004 [51]. 
Since then groups have been attempting to optimize the process for derivation of RPE 
from hESC or iPSC [14, 51].  The main obstacles of culturing pluripotent cell derived 
RPE have always been long derivation time and limited potential for expansion once 
differentiated. Recently, progress has been made in developing more rapid methods for 
differentiation of hESC into RPE [39, 52-54]. For example, Buchholz et al. [39] described 
a method to direct differentiation using a series of growth factors known to play a role 
in RPE differentiation in vivo. However, once RPE are obtained, they still have a limited 
functional lifespan.  
 We report here a novel passaging strategy that relies on inhibition of ROCK that 
results in an increased rate of proliferation and extended passage of both hESC-RPE and 
iPSC-RPE, with retention of function. This phenomenon occurs even when the cells are 
plated at a fourth of the seeding density that is typically used. Thus, one can employ less 
starting material, and passage cells longer, leading to an exponential increase in 
number of cells produced from a single culture of hESC or iPSC.  
 Extended passage hESC-RPE maintained appropriate morphology and gene 
expression of key RPE markers without an increase in pluripotent, fibroblastic or 
endothelial transcripts. Immunocytochemistry of passage 13 hESC-RPE exhibited 
proper localization of RPE transcription factors, proteins involved in pigmentation, 
tight junctions, and proteins important for RPE-specific functions.  Importantly, from a 
therapeutic application perspective, no aberrant proliferation was detected at day 30. 
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Functional analysis demonstrated that passage 13 hESC-RPE were normal with respect 
to ROS phagocytosis and polarized secretion of PEDF and VEGF. In addition, no gross 
genomic abnormalities were detected following ROCK inhibition and repeated passage.  
 How does ROCK inhibition lead to extended passage? Microarray analysis 
suggests that ROCK inhibition could be suppressing an epithelial-to-mesenchymal 
transition (EMT) through various pathways. These include inhibition of key ligands of 
the TGFβ pathway (TGFβ1 and GDF6) [55] and Wnt signaling (WNT5A and WNT5B) 
[56, 57]; along with decreasing levels of collagens 1A1, 4A2 [58, 59], and SNAI2, known 
biomarkers of EMT [60]. RPE are thought to undergo EMT after repeated passages in 
culture, a main reason why hESC-RPE have a finite ability to expand, limiting their 
production for use in transplantation [17, 61]. TGFβ signaling has been shown to be the 
implicated in activating EMT in RPE [17, 55, 62-64]. Furthermore, several investigations 
have predicted the RHO/ROCK pathway is involved in regulating EMT in multiple cell 
types [65-68] , possibly through TGFβ signaling [69]. There has also been evidence 
linking Wnt activation and β-catenin accumulation to the increased expression of EMT 
related genes [56, 70]. Inhibition of ROCK, through addition of Y-27632 or other 
synthetic compounds has already been shown in some cases to reverse this transition 
[71, 72]. Our results are consistent with the idea that decreased expression of TGFβ and 
Wnt signaling transcripts lead to the suppression of EMT. In addition, there could be 
novel, undocumented pathways contributing to the maintenance and increased 
expansion rate of hESC-RPE, which lead to the persistence of RPE identity. 
 Overall, two important processes are affected allowing for an increase in hESC-
RPE expansion. First, ROCK inhibition promotes proliferation by inducing multiple 
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components that are involved in cell cycle progression. This allows RPE to quickly 
reform tight junctions, which is critical to RPE health [73]. Second, ROCK inhibition 
affects many pathways that could be converging to suppress RPE-to-mesenchymal 
transition. This allows hESC-RPE to remain functional for an extended, but finite, period 
in culture.  
The prevalence of AMD for individuals over the age of 40 in the US alone was 
calculated to be 7.2 million people; that number is projected to increase 50% by 2020 
[4]. Assuming that a 3 by 5 mm patch of a hESC-RPE monolayer on a scaffold might be 
developed as a dry AMD therapy, it is estimated that 300,000 hESC-RPE cells will be 
required for each patient transplant [13, 74]. Based on this number, 3.3 trillion cells 
would be required to treat all patients affected in 2020. Following the extended passage 
protocol, a single well of a 6 well plate will generate enough cells in 55 days to treat all 
those calculated to be affected by the disease in 2020. This does not include the 
additional cells that would be required for release assays, quality control and cell loss, 
but the protocol can easily be scaled up. Compared to the current method of derivation, 
the extended passage protocol using ROCK inhibition can exponentially increase the 
yield of mature hESC-RPE to 49 billion from 9 million within the first 60 days in culture, 
over a 5000 fold increase; in addition to using a fourth of the starting cell number. 
 From a cell engineering perspective, it is clear that these discoveries have the 
potential to greatly facilitate the production of functional hESC-RPE and iPSC-RPE for 
both therapeutic and research applications. It is even possible that these findings may 
also be transferable to other epithelial cells derived from pluripotent stem cells. 
Currently, minimally passaged hESC-RPE are being employed in clinical trials. 
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Transitioning to the usage of more highly passaged cells deserve further 
experimentation to characterize their efficacy and potential tumorigenicity in animal 
studies; including a full transcriptome analysis of day 30 Y-27632 treated passage 13 
hESC-RPE to ensure complete restoration of the gene profile to a passage two like state.  
In addition, defining the mechanisms of increased proliferation and suppressed EMT, 
and devising methods to manipulate these processes, could be extremely beneficial in 
developing therapeutics for other RPE dysfunction diseases such as geographic atrophy 
and proliferative vitreal retinopathy, a complication of retinal detachment 
characterized by RPE-to-mesenchymal transition that can lead to loss of vision [64, 75].  
 Inhibition of ROCK activity by the synthetic compound Y-27632 allows extended 
passage of hESC-RPE and iPSC-RPE. Extended passage, in part, seems to be achieved by 
increased proliferation and through the prevention of gene expression that promotes 
and contributes to the mesenchymal phenotype. We have shown that inhibiting ROCK 
allows hESC-RPE and iPSC-RPE to be seeded at a fourth the normal density and grow 
for up to 13 passages. The extended passaged hESC-RPE were comparable to untreated 
early passage hESC-RPE by all parameters tested. This simple technique, in combination 
with the published rapid differentiation protocols, could lead to a faster and more 
efficient way of producing hESC-RPE and iPSC-RPE for clinical trials, basic disease 
research and drug screening. 
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Chapter IV 
 
ROCK Inhibition Promotes Wound Closure and Attachment in Human Embryonic Stem 
Cell Derived Retinal Pigmented Epithelium 
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Introduction 
 Age-related macular degeneration (AMD) is a progressive disease that is the 
leading cause of blindness in the aged population of the developed world [1]. AMD 
initially affects a region in the back of the eye responsible for fine acuity vision called 
the macula. The disease presents when a monolayer of cells called the retinal 
pigmented epithelium (RPE) begin to degrade. The RPE are the critical cell type 
responsible for maintaining the function and viability of the photoreceptors, the main 
light sensing neuron. Therefore when the RPE degrade, the photoreceptors in turn 
begin to die and vision is lost [2, 3].  
 There are two forms of the disease, wet or exudative, and dry AMD. Wet AMD is 
characterized by neovascularization, which disrupts the RPE monolayer. This form, 
although rapidly progressive, can be treated with intraocular injections of anti-VEGF 
antibodies to suppress the overactive blood vessel formation [1]. The dry form, 
affecting 90% of patients diagnosed with AMD, can only be treated with a vitamin 
cocktail and antioxidant supplements, which merely slows disease progression in 25% 
of patients [4, 5]. Geographic atrophy (GA), areas devoid of RPE and subsequently 
photoreceptors, often occurs in late stage AMD patients and is extremely devastating to 
vision. Unfortunately, RPE have limited proliferative abilities to fill in areas affected by 
GA prior to photoreceptor death [6, 7]. Therefore, a human embryonic stem cell (hESC) 
RPE cellular replacement therapy is a promising candidate for a novel, effective 
treatment for ocular diseases that affect RPE [8, 9]; and is currently in clinical trials for 
both AMD and Stargardt’s disease [10, 11]. 
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 Rho-GTPase coiled coil kinase (ROCK) has been known for over ten years to 
affect cytoskeletal rearrangement through the regulation LIMK/cofilin activity [12] and 
is increasingly being studied in a variety of diseases [13]. ROCK inhibition, using 
synthetic inhibitors, is being examined as a treatment option for pulmonary 
hypertension [14], cancer [15], glaucoma [16], and certain neurological diseases [17, 
18]. ROCK inhibition also boosts proliferation rates of hESC-RPE  and allows hESC-RPE 
and iPSC-RPE to be continually passaged in culture for over ten passages prior to 
senescence [19]. Based on the known effects of ROCK inhibition on proliferation and the 
cytoskeleton, we hypothesized that ROCK inhibition would affect wound healing and 
substrate attachment in hESC-RPE.  More recently groups have been identifying a range 
of distinct functions for the two isoforms, ROCK1 and ROCK2 [20-24]. Therefore we 
have examined the effects of a pan ROCK inhibitor as well as a ROCK2 isoform-specific 
inhibitor to elucidate differences in function.  
 ROCK inhibition, using synthetic inhibitors, could provide a combinational 
therapy together with cellular replacement to help promote attachment of transplanted 
cells or could serve as a stand-alone therapy to increase proliferation of endogenous 
RPE to fill in areas affected by GA. This chapter will show that ROCK inhibition 
promotes wound healing and attachment. 
Methods 
Cell Culture 
Pluripotent Stem Cell Culture 
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 H9 human embryonic stem cells (hESC) were acquired from the Thomson group 
and were cultured on Matrigel in mTESR1. Medium was changed every other day and 
cells were kept at 37°C in 5% CO2 in normoxic conditions. 
Retinal Pigmented Epithelium Derivation and Maintenance 
 H9 hESC were overgrown for 8-14 days, followed by the removal of basic 
fibroblastic growth factor and a medium change to XVIVO-10. Cells were cultured for 
90-120 days with a medium change every 2-3 days. After 90-120 days, the non-
pigmented cell patches were manually excised and washed away using phosphate 
buffered saline (PBS). Pigmented patches were lifted from the plate following a 5 
minute incubation at 37°C with TrypLE Express. Cells were then diluted in XVIVO-10, 
spun for 5 minutes at 1000 rpm, and plated at 1.0x105 cells/cm2 on Matrigel-coated 6-
well plates. Every 30 days, these enriched RPE were again enzymatically passaged using 
TrypLE Express. Medium was changed every 2-3 days. Cells used in experiments were 
between passages 1-4. At least three individual enrichments derived from distinct H9 
cultures were used for all analyses; each enrichment equals an ‘n.’ Statistical 
significance was determined by Student’s t-tests for all experiments, comparing two 
experimental data sets at a time. 
Scratch Assay 
 hESC-RPE were grown for 30 days in XVIVO-10. Using a P200 pipet tip, a scratch 
was created down the center of the well from the top to the bottom on day 30. Cells 
were washed 3 times with PBS. 10µM of Y-27632 (ROCK1/2 inhibitor), 10µM of 
ROCKIV (ROCK2 inhibitor), or an equal volume of water as a control was added to cells 
in fresh XVIVO-10 for 14 days post scratch. Immediately following the scratch, cells 
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were imaged along the wound and will be identified as day 0. Three, 7 and 30 days post 
scratch, the cells were imaged again. Quantification of the area of the wound closure 
was determined using the polygonal tool within Image J software to outline the area 
devoid of cells at day 0, and subsequently at days 3, 7 and 30. The areas were then 
subtracted from day 0 area and divided by day 0 area, then made into a percent to 
represent percent wound closure.  
Immunoctyochemistry (ICC) 
 On day 5 and 30 after scratch, cells were fixed with 4% paraformaldehdye in 
0.1M cacodylate buffer for 15 minutes at 4°C. Cells were then blocked with 5% bovine 
serum albumin plus 0.2% Triton X-100 for 1 hour at 4°C. Primary antibody MKI67 was 
diluted in block at (1:1000, Abcam) and incubated at 4°C overnight. The next day, the 
cells were washed 3 times with PBS. The corresponding 488 Alexa Fluor secondary 
antibody (1:300) and Phalloidin conjugated to Tetramethylrhodamine (TRITC, 220µM) 
were added to the cells in PBS for 45 minutes at 4°C (Life Technologies). Hoescht dye 
(2µg/ml) was then added and incubated at 25°C for 5 minutes to stain cellular DNA. 
Cells were washed 3 times and mounted using Prolong Gold Anti-fade. Fluorescent 
microscopy was used to analyze expression patterns at 40X objective on an Olympus 
BX51 Microscope. Fiji and Microsoft Excel software were used to quantify the 
integrated pixel density of MKi67 fluorescence within scratched region and cell area 
was determined by outlining cells within the scratched region using the polygonal tool 
within Fiji and quantifying the area. Twenty cells were analyzed per image using 
internal triplicates and three separate experiments (independent enrichments).  
Attachment Assay 
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 hESC-RPE were passaged as described above, and seeded at 1.0x105 cells/cm2 on 
Matrigel-coated slides in XVIVO-10. At the time of plating, cells were treated with 10µM 
Y-27632, 10µM ROCKIV or an equal volume of water as a control. Cells were allowed to 
attach for 1, 2, 4, 6 and 24 hours. At each time point, attached living cells were stained 
with Calcein AM according to manufacturer’s instructions using a LIVE/DEAD 
Cytotoxicity Kit (Life Technologies). Cells were then fixed for 1 hour at 25°C in 4% 
paraformaldehyde (PFA) in PBS. Fluorescent microscopy was used to image attached 
cells.  Fluorescent quantification was performed with Image J and Microsoft Excel 
software. Each treatment was represented as the percent of the sum total fluorescence 
for the corresponding time point to eliminate the variability of dye intensity between 
experiments, but preserving the change between treatments.  
Cell Spreading Determination  
 hESC-RPE were plated and treated as described in the attachment assay. Cells 
were allowed to attach for 1, 2 and 4 hours. Cells were then fixed in 4% PFA in 0.1M 
cacodylate buffer for 15 minutes at 4°C. Cells were blocked and permeabilized in 5% 
bovine serum albumin plus 0.2% Triton X-100 for 1 hour at 4°C. Phalloidin-TRITC and 
Hoescht were added as described in Immunoctyochemistry. F-actin was visualized 
through fluorescent microscopy at 60X on a BX51 Olympus microscope and cell area 
was analyzed using the Fiji software polygonal tool to outline cells, 20 cells per image in 
internal triplicate. 
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Results 
ROCK inhibition promotes wound closure 
 hESC-RPE were grown for 30 days and then scratched to mimic a wound and 
monitored for an additional 30 days. ROCK1/2 inhibition, added at the time of the 
scratch, significantly enhanced wound closure compared to control by day 3 (Fig. 12A). 
ROCK2 inhibition alone showed significant wound closure by day 3 as well; however 
the cell morphology within the scratched area was large and mesenchymal, not typical 
of the RPE. By day 30, the ROCK1/2-inhibited cells completely closed the wound, while 
the control cells failed to regain a confluent monolayer in the scratched space. ROCK2-
inhibited cells showed significantly more wound closure than control at day 30; 
however the larger cells seen in the earlier time points persisted. The amount of wound 
closure was calculated from photomicrographs and quantified (Fig. 12B). 
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Figure 12. ROCK inhibition enhances wound closure. (A) hESC-RPE were scratched 
following 30 days in culture and treated with either Y-27632 (ROCK1/2 inhibitor) or 
ROCKIV (ROCK2 inhibitor) and wound closure was monitored over an additional 30 
days. Control and ROCKIV-treated cells failed to completely close the wounded area. (B) 
Quantification of wound closure at each time point imaged. Scale bar (A)=200µm (B) 
**p<0.01 compared to control at that time point. +p≤0.05 ++p≤0.01 compared to 
ROCKIV at that time point. Error bars represent ± SEM. n=3.   
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 Interestingly, most of the cells treated with Y-27632 regained their epithelial 
morphology by day 7.  Although control cells failed in fill in the entire scratched area, 
the cells present in the wounded space have mainly recovered their epithelial 
morphology by day 30. In contrast, ROCKIV treated cells, although fast to close the 
wounded area, still had larger and more mesenchymal looking cells compared to 
control and Y-27632 treated cells at day 30.  
ROCK1/2 inhibition promotes proliferation at wound site  
 A general concept of epithelium wound healing is that cells undergo an epithelial 
to mesenchymal transition (EMT) that allows them to migrate into the area devoid of 
cells and form scar tissue [25]. We hypothesized in our wound healing system, based on 
ROCK inhibition’s known effects on proliferation, that the increase in wound closure 
was in part due to an increase in proliferation [19]. Five days after the scratch, cells 
were subjected to immunocytochemistry and probed with MKI67, a proliferation 
marker, and phalloidin, an F-actin probe, to analyze cytoskeletal arrangements (Fig. 
13A). There was a significant increase in MKI67 staining within the wounded area 
following ROCK1/2 inhibition (Fig. 13B). Surprisingly, ROCK2 inhibition showed no 
changes from control in MKI67 expression patterns. However, ROCK2 inhibition 
significantly increased the individual cell size within the scratched region compared to 
both control and ROCK1/2 inhibition treatments, similarly seen in the day 30 images of 
ROCK2 inhibited cells from Figure 12A (Fig. 13C). Importantly, there was no MKI67 
expression detected 30 days post scratch in any of the treatment groups; therefore the 
increase in proliferation due to ROCK1/2 inhibition did not aberrantly continue after  
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treatment was stopped at 14 days after scratch (Supp. Fig. 8). In addition, F-actin 
staining at 30 days post scratch also shows the persistent larger cell size morphology of 
ROCKIV treated cells (Supp. Fig. 8).     
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Figure 13. ROCK1/2 inhibition promotes proliferation in wounded area. (A)  Five days 
after scratch, MKI67, a marker of proliferation (green), Phalloidin (F-actin, red), and 
Hoescht (blue) were examined. (B) MKI67 fluorescence in wounded area was 
quantified and was significantly higher when cells were treated with 10µM of Y-27632. 
(C) ROCKIV increased cell size compared to Control and Y-27632 treatments. Scale bar 
(A)=100µM. (B) *p≤0.05 to control, ++p≤0.01 to ROCKIV. (C) *p≤0.05 to control, 
+p≤0.05 to Y-27632. Error bars represent ± SEM. n=3.  
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ROCK inhibition promotes attachment through an increase in cell spreading 
 ROCK activates LIMK, which inactivates cofilin leading to actin stabilization [12]. 
ROCK is also known to affect cytoskeletal rearrangements through the regulation of 
myosin light chain [26]. Therefore inhibition of ROCK should lead to actin 
depolymerization and the release of actin monomers for the reorganization of the 
cytoskeleton, which could affect cell attachment. hESC-RPE were examined at 1, 2, 4, 6 
and 24 hours after equal-density plating and Calcein AM dye fluorescence was 
determined, which was indicative of the number of attached cells (Fig. 14A, 6 hour 
image representation). ROCK1/2 and ROCK2 inhibition significantly promoted 
attachment of cells as early as 1 hour after plating, and maintained this effect at all time 
points examined (Fig. 14B). ROCK inhibition had a quick acting and significant role in 
hESC-RPE attachment.  
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Figure 14. ROCK inhibition increases cell attachment. (A) At various time points after 
plating, cells were stained with a Calcein AM dye to detect adherent and living cells. 
Fluorescent images at the 6 hour time point are shown for all three treatments. (B) 
Quantification of the percent of the sum total fluorescence for each time point and 
treatment. ROCK inhibition drastically increased cell attachment as early as 1 hour after 
plating. Scale bar (A)=200µm. (B) *p≤0.05 **p≤0.01 compared to control within each 
time point. Error bars represent ± SEM. n≥6. 
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 To examine cytoskeletal organization during cell attachment 
immunoctyochemisty was performed using phalloidin-TRITC (F-actin probe) (Fig. 15A). 
ROCK inhibition significantly increased cell spreading 1 hour after plating when 
compared to control cells, as determined by the calculation of cell area outlined from 
the F-actin fluorescence (Fig. 15B). This effect persisted at 2 and 4 hours after plating. 
ROCK 2-specific inhibition further increased cell spreading at all time points examined 
compared to ROCK1/2 inhibition, distinguishing a specific ROCK2 isoform role in cell 
spreading.  
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Figure 15. ROCK inhibition promotes cell spreading. (A) Fluorescent images taken 2 
hours after plating and stained with phalloidin-TRITC (red) to visualize F-actin and 
Hoescht (blue) to label cellular DNA. (B) Quantification of cell area from phalloidin 
fluorescence. Scale bar (A)=100µm. (B) *p≤0.05 **p≤0.01 compared to control within 
each time point. +p≤0.05 ++p≤0.01 compared to Y-27632 within each time point. Error 
bars represent ± SEM. n=5. 
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Discussion 
 ROCK inhibition, using synthetic inhibitors, is currently in several clinical trials 
for various diseases [27]. ROCK inhibition is thought to prevent the EMT, perhaps 
through inhibition of TGF-β signaling, which often contributes to scarring following a 
wound [19, 25]. In a naïve model of in vitro wound healing, ROCK1/2 inhibition, but not 
ROCK2 inhibition alone, promotes proliferation to fill in the area devoid of cells. Typical 
cobblestone epithelial morphology was quickly regained and the wound was closed 
faster than control when cells were treated with a ROCK1/2 inhibitor. These data could 
distinguish a specific role for ROCK1 in proliferation.  Importantly, this increase in 
proliferation was not predominating elsewhere in the culture and cells exited the cell 
cycle after the wound was closed and treatment was stopped (Fig. 13, Supp. Fig. 8).   
 Interestingly, ROCK2 inhibition initiates wound closure the fastest however did 
not show an increase in proliferation within the scratched area, perhaps pointing 
towards a role for ROCK2 in cell migration and EMT. This would be consistent with the 
change in cell morphology observed in ROCK2-inhibited cultures; away from the 
traditional epithelial cell characteristics, towards a larger, flatter, more mesenchymal-
like cell. ROCK2 treated cells were significantly larger cells within the scratched region 
at day 5 compared to control and ROCK1/2 treated cells.  ROCK1/2 inhibition has been 
shown to inhibit major players in the TGFβ and EMT pathways [19], however these data 
suggest that ROCK2 inhibition alone might promote EMT. This could point towards 
opposing and specific roles for ROCK1 and ROCK2; ROCK2 in inhibiting EMT, while 
ROCK1 may promote EMT, in this system. Unfortunately, at this time there are no 
ROCK1 specific inhibitors; therefore, hESC-RPE siRNA knockouts of ROCK1 and ROCK2 
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need to be examined to fully test this theory. A closer examination of ROCK inhibition in 
wound healing could prompt a novel therapeutic for GA, a devastating progression of 
AMD. 
 ROCK has been known for years to stabilize actin fibers and promote stress fiber 
formation through its regulation of LIMK and MLC [12]. Current literature has 
repeatedly shown that ROCK inhibition destabilizes actin polymerization [28]; however 
here, we found that ROCK inhibition increases cell attachment. We believe this is due to 
the reorganization of actin fibers. LIMK is activated by ROCK1/2 and inactivates cofilin, 
stabilizing actin [29]. ROCK inhibition therefore activates cofilin and initiates the 
depolymerization of actin fibers. This creates a pool of F-actin monomers that by a 
mechanism not yet known, could be contributing to the creation of new F-actin fibers 
and focal adhesion complexes, promoting attachment. In contrast to other ROCK 
inhibition data, we found an increase in cell spreading within the first hour after plating 
following ROCK inhibition compared to control [30]. Interestingly, there was a 
significantly greater effect in cell spreading with ROCK2 inhibition alone, perhaps 
correlating to the wound assay hypothesize that ROCK2 inhibition promotes larger 
mesenchymal cells through the initiation of EMT.  
 The effects of ROCK inhibition on attachment could be extremely beneficial in 
hESC-RPE cellular therapies involving bolus injections of cells, as in the ACT clinical 
trial for AMD [10, 11]. It also provides a new, fast acting role for ROCK inhibition in 
attachment of hESC-RPE. hESC-RPE are generally plated at a high seeding density, but 
through the use of ROCK inhibition, we can combine the beneficial effects of an increase 
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 in cell attachment with the known effects of increased proliferation to seed RPE at a 
lower density to save time, money and amount of these precious cells. ROCK inhibition’s 
role in attachment should also be examined for other cellular therapies with poor 
integration to try to overcome this obstacle. 
 Although at the beginning stages, this work provides valuable insight into the 
effects of specific isoform ROCK functions on hESC-RPE and could lead to the formation 
of a novel treatment to be used alone or in combination with cellular therapies to help 
restore the RPE in various ocular diseases. Furthermore, ROCK inhibition treatment 
could cross over to other diseases where epithelial layers are compromised, or be used 
to help prevent post-operative scarring as is common in glaucoma surgeries [27]. 
 Aside from the implications in ocular disease, ROCK inhibition is under 
investigation as an anti-metastatic agent to prevent migration in various cancers [31]. 
Most researchers have examined the effect of ROCK inhibition on migration, however 
the data presented here should open up research avenues to elucidate ROCK 
inhibition’s role in attachment of tumor cells and EMT, a characteristic of metastatic 
tumor cells [32].  It was recently published that ROCK inhibition can promote the 
reattachment of breast cancer cells in circulation, which correlates with our conclusions 
[33]. The role of ROCK inhibition in attachment and EMT described in this chapter 
warrant further examination in a cancer-based system for the possible development of 
a cancer therapeutic. 
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Chapter Five 
 
Monitoring Stem Cell Transplants in Ocular Disease: Creating a Molecular Tool Basket 
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Introduction 
  Current research for development of an Age-related Macular Degeneration 
(AMD) therapeutic focuses on using human embryonic stem cells (hESC) derived cells as 
a cellular replacement therapy [1, 2]. hESCs spontaneously differentiate into retinal 
pigmented epithelium (RPE) after the removal of basic fibroblastic growth factor and 
can be enriched to create a homogenous population of cells [3, 4]. In the US, clinical 
trials are already underway using a bolus injection of hESC-RPE into the eye [1, 5]. In 
addition, a second transplantation approach is being studied [6, 7] that involves 
culturing hESC-RPE on a synthetic substrate [8] and transplanting the monolayer into 
the eye.  It has been shown that transplantation as a monolayer improves cell survival 
and decreases cell dispersion from site of implantation and allows for better graft 
control and traceability [9, 10]. However all these studies have been done using end 
point analyses. 
 Stem cell transplantation does have potential caveats, including transplanted cell 
migration [11], proliferation [12, 13], death [14, 15], immune rejection [16-18], and 
teratoma formation [13, 19]. There is potential for devastating effects if these events 
occur [20]. Surprisingly, these behaviors have yet to be sufficiently studied in either 
method of hESC-RPE transplantation in real time [1, 21]. 
 To address these issues we have created molecular tools to examine parameters 
of cell identity, function, proliferation, migration, and population homogeneity post-
transplantation. This will provide a more complete view of cell behavior after 
implantation and further compare transplantation methods.  Key characteristics of 
hESC-RPE cells can be monitored using a reporter system, where fluorescent color 
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indicates a specific cell process. We have created four reporters to monitor migration, 
identity, maturity and mitosis (Table 2). Through the use of fundus autofluorescence 
and optical coherence tomography imaging techniques, we would be able to follow 
these reporters after transplantation within the same animal in real time. This will 
elucidate novel data about how the hESC-RPE responds to the retinal environment, how 
cells are incorporated, and how the hESC-RPE behaves at multiple time points. In 
addition, the two transplantation methods can be extensively compared to bring the 
best strategy to the clinics to ensure optimal surgical outcome for patients. 
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Table 2. A list of the processes monitored by the reporter system (left column). The 
promoter region of a specific gene (middle column) has been cloned to drive expression 
of the reporter gene (right column). All reporters were cloned using a lentiviral 
supporting backbone. EF1α=elongation factor 1α, BEST1=bestrophin-1, RPE65=retinal 
pigmented epithelium 65kDa, MKi67=marker of proliferation Ki-67 eGFP=enhanced 
green fluorescent protein, copGFP=copepod green fluorescent protein 
Process Monitored Promoter Reporter 
Migration/Survival EF1α eGFP 
RPE function/identity BEST1 copGFP 
RPE function/maturity RPE65 copGFP 
Mitosis MKI67 eGFP 
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Methods 
Reporter Cloning 
 The elongation factor 1α-enhanced green fluorescent protein (EF1α-eGFP) 
reporter was obtained from Addgene (Plasmid #12247). The marker of proliferation Ki-
67(MKi67)-eGFP reporter was kindly donated from Alexander Zambon from the 
University of California, San Diego [22]. The bestrophin-1 (BEST1) promoter region was 
donated by Noriko Esumi at the Nagoya University School of Medicine, Japan [23]. The 
BEST1 promoter was subcloned into the multiple cloning site of the pGreenFire Lenti-
Reporter plasmid from Systems Biosciences (SBI), to drive copepod GFP (copGFP), 
positioned directly downstream (SBI, California, USA). The retinal pigmented 
epithelium 65kDa (RPE65) promoter region was annotated in [24] and primers were 
created around this region (Forward: 5’ AT GCC CTC ACT GTA AGG AAA TG 3’; Reverse: 
5’ GA TCC AGA GTT CTG GCA CCA A 3’). Genomic DNA (gDNA) from day 30 hESC-RPE 
was isolated using the Promega Wizard genomic DNA isolation kit (Promega, Wisconsin, 
USA). The RPE65 promoter region was isolated from gDNA using PCR. Then the 
promoter was ligated into the pGreenFire Lenti-Reporter, oriented to drive the 
plasmid’s endogenous copGFP. All completed reporters were confirmed by sequencing 
performed by Eton Bioscience Inc. (Eton Bioscience Inc., California, USA).  
Cell Culture  
 Human embryonic kidney 293 cells (HEK293) used for viral production were 
obtained from ATCC and cultured in Dulbecco’s Minimum Essential Media+Glutamate 
(DMEM, Life Technologies) on tissue culture plastic. 
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  hESC H9 cells, donated from J. Thomson, were allowed to overgrow for 8-14 
days in mTESR medium on Matrigel. The medium was then changed to XVIVO-10 
medium containing no basic fibroblast growth factor (bfgf). Ninety days after the 
removal of bfgf, pigmented patches were enriched [4, 25]. Briefly, the non-pigmented 
cells were manually dissected and washed away with phosphate buffered saline (PBS). 
Pigmented patches were enzymatically digested with TrpLE express for 5mins at 37°C. 
Cells were then scraped, diluted in 1:10 volumes of XVIVO-10, spun at 1000rpm for 
5mins and seeded at 1.0x105cell/cm2, yielding a homogenous hESC-RPE population. 
hESC-RPE were maintained in XVIVO-10 on Matrigel coated tissue culture plates, and 
enzymatically passaged every 30 days in the same method described above.  
 A negative control cell line, human umbilical vein endothelial cells (HUVECs), 
was cultured in Endothelial Growth Medium I (EGM) on 0.1% gelatin coated tissue 
culture plates. All cells were grown at 37°C 5% CO2 in normoxic conditions.  
Virus Production 
 Lenti-viral envelope (Plasmid # 12259) and packaging (Plasmid # 12260) 
plasmids were obtained from Addgene. These plasmids in combination with each 
reporter plasmid were tranfected into HEK293 cells using a calcium phosphate method. 
The transfection was stopped after 16h by aspirating the medium and adding fresh 
DMEM medium. This medium was subsequently collected at 48h and 72h after the 
initial transfection. Viral particles were concentrated using a PEG-it solution (SBI) and 
stored at -80°C until use.  
Transduction of Viral Particles  
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 hESC-RPE and HUVECs were transduced with viral particles immediately 
following cell passage, allowing particles to attack the cells on all sides, leading to a 
higher efficiency of infection. Antibiotic resistance was conferred within the viral 
genome of each reporter except the EF1α-eGFP vector. Both BEST1-copGFP and RPE65-
copGFP reporters conferred resistance to neomycin, while MKi67-eGFP contained a 
blasticidin resistant gene. To select for cells expressing the reporters the BEST1-copGFP 
and RPE65-copGFP hESC-RPE cultures were treated with G418 at 400µg/ml and the 
MKi67-eGFP hESC-RPE culture with 4ng/ml of blasticidin for 3-10 days post-infection. 
 Cells were monitored over one month using an Olympus IX71 fluorescent 
microscope to ensure reporters maintained efficient tracking of desired behavior.  After 
30 days in culture the hESC-RPE containing the reporters were passaged and frozen 
down 2 days after plating. Cells were frozen in CryoSTOR10 and stored in the liquid 
nitrogen, forming four intermediate cell banks, one for each reporter. 
Seeding of parylene substrates 
 Parylene substrates were obtained from California Institute for Technology 
through our collaboration for the California Project to Cure Blindness. Substrates were 
placed in a 24 well plate and washed twice with 70% ethanol for 15mins, then twice 
with PBS containing magnesium and calcium for 15mins. A 14.5mm cylinder ring was 
placed within the well to hold the substrates down. The substrates were coated with 
10µg/ml human vitronectin (BD Biosciences, California, USA) for 2 hours at room 
temperature. Cells were then passaged and seeded onto coated substrates at 3.0x105 
cells per well in XVIVO-10 medium. 24-48 hours after initial seeding, substrates were 
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moved to a new 24 well plate and cultured for 30 days with a medium change every 2-3 
days. 
Results 
EF1α-eGFP was constitutively expressed in hESC-RPE 
 The elongation factor 1 α promoter region is commonly used to drive expression 
of exogenous transgenes [26]. We utilized the ubiquitous and strong expression of the 
EF1α promoter to create a reporter that was constitutively active within our hESC-RPE. 
hESC-RPE were transduced with the EF1α-eGFP virus created as described in the 
Methods section. Thirty days after infection, hESC-RPE efficiently and continuously 
expressed eGFP (Fig. 16A). Although the cells expressing the exogenous reporter were 
not selected for, high efficiency of viral incorporation was achieved. In addition, hESC-
RPE containing the EF1a-eGFP reporter were passaged onto a vitronectin coated 
parylene substrate and grown for thirty days, with maintained eGFP expression (Fig. 
16B). In the future, these monolayers could be transplanted into a rat model of retinal 
dystrophy. This reporter will be useful for examining transplant location and cell 
migration.  
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Figure 16. hESC-RPE transduced with EF1α-eGFP lentivirus, 30 days post-infection. (A) 
The uninfected cells show no eGFP expression, left panel; while the cells infected with 
the reporter show a high efficiency of eGFP expression, right panel. (B) hESC-RPE 
infected with the EF1α-eGFP reporter have been seeded onto a parylene substrate for 
transplantation. Scale bar (A)=100µm. Scale bar (B)=200µm. 
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BEST1-copGFP and RPE65-copGFP monitor hESC-RPE cell identity and maturity 
 BEST1 is found specifically in RPE and is believed to be a calcium activated 
chloride channel [27].  It is necessary for maintaining proper membrane conductance of 
the RPE, essential for functional vision [28]. hESC-RPE cells transduced with the BEST1-
copGFP reporter expressed BEST1 indicated by the presence of copGFP (Fig. 17). In 
uninfected hESC-RPE and infected HUVECs (a negative control cell line), there was no 
transcription of BEST1 indicated by the lack of copGFP expression, supporting the 
specificity of the reporter to BEST1 expression within RPE. 
 RPE65 is a visual cycle protein found in mature RPE. It is required for all trans to 
11-cis-retinoid isomerization, a critical step in recycling components involved in 
maintaining the photoreceptors’ light sensing abilities [29]. RPE, not HUVECs, fluoresce 
copGFP following transduction of the RPE65-copGFP reporter indicating that this 
reporter was specific to RPE (Fig. 17).  
 These reporters will be useful to identify whether monolayer transplanted RPE 
maintain their mature markers of RPE identity, which could give insight into their 
functional abilities. In particular, it will help elucidate whether the bolus injection of 
hESC-RPE are able to mature after injection. 
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Figure 17. RPE specific reporter expression. BEST1, an RPE specific chloride channel, 
drives expression of copGFP. This expression was specific to RPE cells and not seen in 
uninfected hESC-RPE or infected HUVECs (negative control cell line) (left panel). 
RPE65, a mature protein in the visual cycle, was reported only in hESC-RPE (right 
panel). Scale bar=100µm. 
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MKi67-eGFP track cells undergoing mitosis 
 MKi67 is a critical component in cell cycle regulation [30]. hESC-RPE were 
transduced with a MKi67-eGFP reporter upon plating and monitored over 30 days (Fig. 
18). hESC-RPE primarily proliferated during the first 8 days, as seen through expression 
of eGFP on day 3 and 8. The signal may appear less intense at day 3 than day 8 possibly 
because the cells were still building up eGFP to visible levels following the integration, 
transcription and translation of the exogenous transcript. The cells then began to shrink 
down and drop out of the cell cycle, depicted by the decrease in reporter expression 
from day 8 to 12. By day 30, minimal eGFP was detected. Although there was a small 
patch of fluorescent cells, this could be hESC-RPE re-entering the cell cycle to fill an area 
that underwent cell death. The MKi67-eGFP reporter will be useful for accurately 
monitoring cells within the cell cycle and give insight into whether there is aberrant 
proliferation upon transplantation. 
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Figure 18. hESC-RPE were transduced with MKi67-eGFP upon plating and monitored 
over 30 days. MKi67 expression followed the known hESC-RPE proliferation timeline. 
hESC-RPE divide throughout the first 3-12 days and then shrink down and exit the cell 
cycle. Scale bar=100µm. 
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Discussion 
 Current work has created four reporters: the EF1α promoter driving eGFP 
expression, the BEST1 promoter driving eGFP, the RPE65 promoter driving eGFP, and 
the MKi67 promoter driving eGFP. EF1α, a constitutive marker, can track migration of 
transplanted cells; BEST1 and RPE65, more functional RPE genes, monitor mature RPE 
identity; while MKi67 will report any cells undergoing mitosis, a large concern of the 
FDA in stem cell therapies. All reporters have been transduced into hESC-RPE and ICBs 
have been created.  Fluorescent color of the cells will correspond to the specific cell 
behavior, allowing transplanted hESC-RPE to be monitored in real time within the same 
animal. 
 Utilizing the power of these reporter cells in various animal models of ocular 
disease in which the RPE are affected, will be critical in progressing stem cell therapies 
towards successful outcomes in the clinic. They will give us valuable insight, through 
real time imaging, of how transplanted cells behave. Imaging specialists can carry out in 
vivo optical coherence tomography and fundus autofluorescence confocal scanning 
laser opthalmoscope techniques to analyze cell characteristics at various time-points 
after surgery. Optokinetics tests could monitor any changes in visual function to support 
reporter imaging data. In addition, further determination of the optimal surgical method 
could be uncovered through reporter expression patterns and optokinetic scores. 
 The overall goal of the creation of these molecular tools is to identify key 
behaviors of transplanted hESC-RPE to ensure the best surgical outcome for those 
suffering from the advanced form of Dry AMD and other ocular diseases. The ICBs of 
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hESC-RPE reporter lines await collaboration and transplantation to fully utilize their 
potential. 
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Supplemental Table 1. Line-to-line variation in iPSC-RPE derivation based on 
derivation protocol. 
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Supplemental Figure 1. Contaminate marker transcripts levels. (A) DF4, DF19 and 
Mycell iPSC-RPE contaminate markers are significantly lower than positive control 
values (p≤0.05). Positive control cell values for non-RPE genes: H9 hESC, Rex 1 
(4.09±0.09), Sall4 (10.93±0.45); SMC, ITGA2 (2.02±0.24); HUVEC, PECAM (15.7±0.53); 
SH-SY5Y, MAP2 (0.78±0.29). (B) S100A4 contaminate expression for DF4, DF19 and 
Mycell iPSC-RPE are significantly lower than positive control, (p≤0.05) Hs27, S100A4 
(20.13±1.09). Normalized to geometric mean of housekeepers, See Methods in Chapter 2. 
Error bars represent ± SEM. n=3.   
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Supplemental Figure 2. Gene expression profiles for hESC-RPE passage 3 day 30 after 
thaw. RPE specific transcripts and PAX6, a neural retina marker, left panel. 
Pigmentation markers, right panel. (A) SCAC-derived H9 hESC-RPE gene profile. (B) 14-
day-derived UCSF4 hESC-RPE gene profile. The two different hESC lines cannot be 
directly compared. Normalized to geometric mean of housekeepers, See Methods in 
Chapter 2. Error bars represent ± SEM. n=3. 
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Supplemental Figure 3. Protein localization and expression in hESC-RPE. 
Immunofluorescence images of OTX2, MITF, PMEL, RPE65, ZO-1, and TRA1-81 are 
shown for passage 3, day 30 hESC-RPE derived by SCAC (H9-RPE) or 14-day directed 
differentiation (UCSF4-RPE). Scale bar represent 50µm. 
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Supplemental Figure 4. iPSC-RPE phagocytosis compared to hESC-RPE phagocytosis. 
Rod outer segments (ROS) in the absence (white bars) or presence (black bars) of anti-
αVβ5 represented as a percent of ROS fRPE integrated pixel density. (A) Phagocytosis of 
SCAC-derived DF4, DF9 and MyCell iPSC-RPE compared to SCAC-derived H9 hESC-RPE. 
DF4 and DF19 iPSC-RPE phagocytose less than H9 hESC-RPE. (B) 14-day-derived DF4, 
DF9 and MyCell iPSC-RPE compared to 14-day-derived UCSF4 hESC-RPE phagocytosis. 
MyCell iPSC-RPE phagocytose more than UCSF4 hESC-RPE. Reference Chapter 2 
Methods for normalization method and statistics. Error bars represent ± SEM. *p≤0.05, 
compared to hESC within the same method. n=3. 
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Supplemental Figure 5. Bright-field images of control passage 2 (left) and Y-27632 
treated passage 13 (right) cells show similar patterns of pigmentation at day 30. Scale 
bar=100µm. 
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Supplemental Figure 6. Cytogenetic analysis reveals normal human female 46, XX 
karyotype for hESC-RPE passage 3 (top panel) and passage 13 (bottom panel) from the 
same enrichment. Y-27632 treatment does not create chromosome abnormalities.  
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Supplemental Figure 7. The microarray data was transformed using the ratio: log2(Y-
27632/Control) and put into the DAVID clustering software. Cell processes were 
graphed according to p-value. The number of genes within the cluster is indicated at the 
right of each bar. 
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Supplemental Figure 8. Day 30 after scratch of hESC-RPE showed no residual MKI67 
expression. hESC-RPE were scratched and treated with either 10µM Y-27632, 10µM 
ROCKIV or equal volume water as a control and immunocytochemistry was performed 
following 30 days in culture. Treatments were stopped after 14 days. (A) Left panel, 
MKI67 staining, right panel, overlay of Hoescht (blue, cellular DNA), Phalloidin (red, F-
actin), and MKI67 (green, proliferation). (B) Quantification of intensity of MKI67 
fluorescence following ICC within scratched region. Some residual integrated pixel 
density was detected by the software; however this was background. Scale bar 
(A)=200µm. Error bars represent ± SEM. n=2. 
 
 
 
 
 
 
 
 
 
 
